

SPECIAL Report

New Molecular Entities Listed in 2023

A Synopsis of the Key Drugs Listed in 2023 - their positioning and how they are going to impact the market landscape.

Date of Release | 2024. 11.22 Analyst | Devesh.Singh



Monitoring Pharmaceutical Industry for the Society

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

INDEX

SPECIAL Report

2024.11

04 Overview of New Molecular Entities Listed in 2023

- 07 Drugs Containing New Active Ingredients & Listed under
 Over ¥10 Billion of Peak Sales Potential^{*1}
 - 07 Altuviiio FVIII replacement therapy with once-weekly dosing
 - Besremi a significant advancement in the treatment of polycythemia vera
 - 14 Empaveli the first and only C3 inhibitor for PNH
 - 18 Epkinly the first anti-CD20xCD3 bispecific antibody for LBCL
 - 21 Leqembi the first disease-modifying therapy for AD
 - 24 Leqvio the first siRNA therapy for hypercholesterolemia
 - 27 Litfulo the second approved drug for alopecia areata
 - **30** Mounjaro first GIP/GLP-1 dual receptor agonist for T2DM
 - 33 Omvoh first IL-23 inhibitor in the crowded UC market
 - 36 Phesgo subcutaneous FDC of Perjeta and Herceptin
 - 39 Phozevel a first-in-class phosphate absorption inhibitor
 - 42 Rystiggo gMG treatment for the two main sub-types

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved. Unauthorized quoting, copying and reproduction of the contents of this report are prohibited.

2

45	Prof	ile of New Molecular Entities Listed in 2023,	55	Lytgobi
	excl	uding the drugs which are described above	55	Oncaspar
	45 Tavalisse		56	Acthib
	45	Cresemba (Oral)	56	Luxturna
	46	Paxlovid	57	Korsuva
	46	Monover	57	Megludase
	47	Erwinase	58	Zilbrysq
	47	Imjudo	58	Alhemo
	48	Libtayo	59	Cuvitru
	48	Adtralza	59	Fetroja
	49	Cresemba (Injection)	60	Appendix: New Molecular Entities Approvals in Past
	49	Allydone		10 Years – Key Statistics (Figures only)
	50	Хосоvа	60	New Molecular Entities vs Peak Sales
	50	Doptelet	60	New Molecular Entities Listing by Formulation Type
	51	Orphacol	61	New Molecular Entities Listing by Pricing Method
	51	Vyalev	61	New Molecular Entities Listing by PMP vs Non-PMP
	52	Omvoh (Maintenance therapy)	<mark>62</mark>	New Molecular Entities Listing by Sponsor's Origin of
	52	Palynziq		Country
	53	Atgam	<mark>62</mark>	New Molecular Entities Listing by Type of Modality

^{*1}...Drugs indicated for "SARS-COV2 infection" are in the section "Profile of new molecular entities Listed in 2023, excluding the drugs which are described above", not in the section "Drugs Containing New Active Ingredients & Listed Under over ¥10 Billion of Peak Sales Potential".

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

53 Nexobrid

54 Sunlenca (Oral)

54 Sunlenca (Injection)


Research Report | Copyright © 2024 Encise Inc. All Rights Reserved. Unauthorized quoting, copying and reproduction of the contents of this report are prohibited.

3

Overview of New Molecular Entities^{*2} Listed in 2023

In 2023, a total of 42 new molecular entities (NMEs) were listed in Japan. This count was smaller than the count of NMEs listed a year ago in the 2022 (47 new drugs), however the combined peak sales estimate for 2023 was higher (¥468 Billion vs. ¥360 Billion).

Oncology continues to be the largest contributor for NMEs flow and a total of 8 new drugs from oncology were listed. It was followed by 4 each from "Blood Coagulation System, Products" and "Antivirals for Systemic Use" (Figure 1).




Source: MHLW, Encise Research Center

Figure 1. New Molecular Entities Listing in 2023 by Therapeutic Category

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

On pricing method front – maximum 31 drugs were priced by 'similar efficacy comparison method (I)', followed by 11 from the 'cost accounting method' (Figure 2).



Source: MHLW, Encise Research Center


Figure 2. New Molecular Entities Listing by Price Method

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved. Unauthorized quoting, copying and reproduction of the contents of this report are prohibited.

5

Out of these 42 NMEs, 14 are expected to have over ¥10 Billion of peak sales potential and 29 have received 'price-maintenance premium'. Out of these 42, 16 are biologics and 11 are listed under orphan drug status. (Figure 3 to 6).





New Molecular Entities Listings by Different Categories

A more comprehensive overview of NMEs listing in past 10 years is provided under the appendix of this report (figure 7 to figure 12).

^{*2}...The report includes all 'ethical drugs' approved as drugs containing new active ingredients and 'human cell therapy and gene therapy products' categories specified by the MHLW.

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved. Unauthorized quoting, copying and reproduction of the contents of this report are prohibited.

6

Drugs Containing New Active Ingredients & Listed under Over ¥10 Billion of Peak Sales Potential

Altuviiio - FVIII replacement therapy with once-weekly dosing

		Drug Prot	file - Altuviiio		
Molecule Type	Biologics(not mAb)	Molecule	Efanesoctocog alfa (genetical recombination)	Brand	Altuviiio
Launch Month	November 2023	Form	Injection	Strength	250/vial (with solution) 500/vial (with solution) 1,000/vial (with solution) 2,000/vial (with solution) 3,000/vial (with solution) 4,000/vial (with solution)
Therapeutic Classes ^{*3} (2nd level)	Blood Coagulation System Products	Mechanism of Action	Hemostasis/Replacement of blood coagulation factor VIII		
Therapeutic Classes ^{*3} (3rd level)	Blood Coagulation Products	(MOA)		or blood codgalado	
Indication	Suppression of bleeding t	endency in patients with	h blood coagulation factor	VIII deficiency	
Manufecturer	Sanofi	Marketer	Sanofi	Originator/s	Amunix Pharmaceuticals
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥49,543, ¥99,085, ¥198,171, ¥396,341, ¥594,512, ¥792,683	Peak Sales (Predicted ^{*4})	¥19.1 Billion
Total Sales of the Therapeutic Category (Blood Coagulation Products) *5					¥151 Billion
Contribution of the Brands in the Category (Blood Coagulation Products) *5					100%
Hospital (≥100 beds)	Sales Ratio in the Category	(Blood Coagulation Pro	oducts) *5		78%

^{*3}...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

Altuviiio is a factor VIII replacement therapy for hemophilia A and was listed and launched in November 2023.

The Drug: Altuviiio is a factor VIII replacement therapy for Hemophilia A which delivers normal to near-

normal factor activity levels with once-weekly dosing, as compared to the existing replacement therapies, which need to be given twice or three times each week.

Anyone who has read the report is deemed to have agreed to the Terms of Use.

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Pricing and Peak Sales Potential: Altuviiio's price was set by comparing it with Bayer Yakuhin's Jivi (recombinant damoctocog alfa pegol) as the reference, and it was granted a 5% utility premium (II). According to the data submitted to Chuikyo, Altuviiio is expected to generate peak sales of ¥19.1B in the 10th year, treating 669 patients. Despite the peak sales forecast exceeding ¥10B, Altuviiio will not be subject to the CEA, as drugs exclusively used for rare diseases such as hemophilia are excluded from the system's scope.

About the Indication: Hemophilia A is a rare lifelong condition which hampers blood clotting, leading to excessive bleeds that may cause joint damage, chronic pain, and affect quality of life. Its severity depends on clotting factor activity levels. Hemophilia A entails a deficiency of clotting factor VIII (FVIII), necessitating lifelong prophylactic treatment, often with recombinant FVIII. Altuviiio is a factor VIII replacement therapy approved for routine prophylaxis, on-demand treatment, and surgical management for adults and children.

When an injury causes a bleed, a process known as hemostasis occurs at the injury site to form a clot and stop the bleed. Hemostasis is achieved in 2 parts – 1.) Primary hemostasis, where platelets gather at the injury site aided by von Willebrand Factor (vWF) to create a "platelet plug" reducing blood loss, and 2.) Secondary hemostasis, where the clotting cascade generates a fibrin mesh around the platelets to stabilize the clot. Without enough Factor VIII, body's ability to generate thrombin is reduced. The amount of Factor VIII in blood is measured under "factor activity level" and when it is less than 1% of the normal level, it is considered Severe hemophilia. Hemophilia due to deficiency of factor IX is known as Hemophilia B.

Clinical Data: The approval of Altuviiio was backed on the results from a phase 3 study called XTEND-1. The data from this study published in NEJM showed that Altuviiio met primary and key secondary endpoints, demonstrating clinically meaningful prevention of bleeds and superior bleed protection compared to prior factor VIII prophylaxis based on an intra-patient comparison. More specifically, the results demonstrate that Altuviiio delivered normal to near-normal factor activity levels (>40%) for the majority of the week with once-weekly dosing.

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved. Unauthorized quoting, copying and reproduction of the contents of this report are prohibited.

8

Positioning & Market Outlook: Until 2006, all available factor VIII products used human or animal blood-derived components at some stage in manufacturing or formulation. Advate (from Baxter) was approved in 2006 in Japan, was the world's first and only recombinant factor VIII therapy processed without any human or animal-derived protein indicated for the hemophilia A. It reduced the potential risk of infections that may be caused by pathogens carried in human or animal-derived additives.

The Hemophilia A market landscape has changed significantly in recent years after entry of a number of 'genetically recombinant' factor VIII replacement therapies with longer duration of action. Altuviiio differentiates itself from the competition due to its extended half-life, which is three to four times longer than rival therapies as per Sanofi. Current factor VIII products cause levels to go up but decrease quickly, meaning patients have to go in for routine prophylaxis every two days. By contrast Altuviiio's weekly dosing.

Hemlibra is leading this market – however, it is bispecific antibody for factor IX and X and hence it is indicated for hemophilia A with or without factor VIII inhibitors.

A number of new candidates are under development for hemophilia including gene therapies, and we are likely to see new drugs in future. Pfizer has filed Marstacimab in March 2024. It is indicated for both hemophilia A or hemophilia B without inhibitors to factor VIII (FVIII) or factor IX (FIX).

An Interesting Fact: Hemophilia A medications, which are factor VIII replacement therapies, commonly use the 'ate' suffix in their names to denote factor VIII (eight or 8). Examples include Recombinate (Rurioctocog alfa from Baxter), Advate (Rurioctocog alfa, genetically recombinant, launched in 2020 by Takeda), Eloctate (launched in May 2019 by Sanofi) etc. However, Altuviiio stands out as the first drug to incorporate the Roman numeral VIII into its brand name. Likewise, treatments for hemophilia B, which are factor IX replacement therapies, often incorporate 'IX' in their names, such as Benefix, Alprolix, Ixinity, Hemgenix etc.

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Table 1. Select Drug Candidates for Hemophilia A °				
Brands (Molecule) Marketer	Launch	2023	Dose Prophylaxis ^{*7}	
	Launch	Sales		
Coagulation factor VIII replacement – for Hemophilia A				
Altuviiio (Efanesoctocog alfa, GR) Sanofi	2023	n/a	1x wk	
Adynovate (Rurioctocog alfa pegol, GR) Takeda	2020 ^{*8}	¥16.8B	2X wk	
Advate (Rurioctocog alfa, GR) Takeda	2020 ^{*8}	¥4.4B	3x-4x wk	
	2019 ^{*9}	¥11.8B	Initially 2x wk then	
Eloctate (Efraloctocog alfa, GR) Sanofi			every 3-5days	
			Initially 2x wk then	
Jivi (Damoctocog alfa pegol, GR) Bayer	2019	¥4.4B	every 5days	
Bispecific antibody (for factors IXa and X) - Hemophilia A				
Hemlibra ^{*10} (Emicizumab, GR) Chugai	2010	VCAOD	Loading 1x wk for 4wk,	
	2018	¥64.0B	then ever 2 or 4 weeks	
All are constic recombinant drugs		•		

Table 1. Select Drug Candidates for Hemophilia A^{*6}

*6...All are genetic recombinant drugs

*7...normal dose, may vary

^{*8}...Takeda's launch year

*9...Sanofi's launch year

^{*10}...Hemlibra is indicated for hemophilia A with or without factor VIII inhibitors.

Source: Encise Research Center, Company Reports

Overseas Status: The drug obtained US approval in February 2023 under the Altuviiio brand (by Sanofi and Sobi). In Europe, the European Medicines Agency (EMA) has accepted and verified marketing authorization application for Altuviiio in May 2023.

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Besremi - a significant advancement in the treatment of polycythemia ver	а
--	---

	Drug Profile - Besremi				
Molecule Type	Biologics(not mAb)	Molecule	Ropeginterferon alfa-2b (genetical recombination)	Brand	Besremi
Launch Month	June 2023	Form	Injection	Strength	250μg/0.5mL/syringe 500μg/mL/syringe
Therapeutic Classes ^{*3}	Immunostimulating				
(2nd level)	Agents	Mechanism of Action	Activation of call growth in	hibiton, cianals	
Therapeutic Classes ^{*3} (3rd level)	Interferons	(MOA)	Activation of cell growth inhibitory signals		
Indication	Polycythemia vera (limited	to cases in which existi	ng treatments are inadequa	ate or inappropriate)	
Manufecturer	Pharmaessentia Japan	Marketer	Pharmaessentia Japan	Originator/s	PharmaEssentia Corporation
Price Maintenance Premium (PMP)	Not applied	Unit Price (at the time of first listing)	¥297,259, ¥565,154	Peak Sales (Predicted ^{*4})	¥16.3 Billion
Total Sales of the Therapeutic Category (Interferons) *5					¥44 Billion
Contribution of the Brands in the Category (Interferons) ^{*5}					100%
Hospital (≥100 beds)	Sales Ratio in the Category	(Interferons) *5			84%

^{*3}...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

 $^{\rm *5}$... the rapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

PharmaEssentia launched Besremi in June 2023 as its first product in Japan for polycythemia vera (PV). It won Japanese regulatory approval in March and joined the NHI price list in May.

The Drug: Ropeginterferon alfa-2b is a novel, mono-pegylated, long-acting proline interferon. It works by binding to the interferon alfa receptor (IFNAR) in the bone marrow. It has an inhibitory effect on the proliferation of hematopoietic stem cells, and is thought to decrease the mutated JAK2 (V617F) burden. Its pharmacokinetic properties have been enhanced for longer dosing intervals compared to conventional pegylated interferon.

Pricing and Peak Sales Potential: Besremi was priced under the cost-based method and was given price tag of $\pm 297,259$ for its 250 µg version and $\pm 565,154$ yen for 500 µg. Besremi is expected to generate peak sales of ± 16.3 billion in the 10th year, treating 1,700 patients. It is subject to the cost-effectiveness assessment scheme.

Marketing and Distribution: Besremi is the first product of PharmaEssentia in Japan. PharmaEssentia Japan was established in 2017 as a Japanese subsidiary of the Taipei-headquartered biopharma. PharmaEssentia has set up a stand-alone marketing organization in Japan.

About the Indication: Polycythemia Vera (PV) falls under myeloproliferative neoplasms (MPNs), a group of blood cancers. PV involves a mutation in a single stem cell in the bone marrow, leading to overproduction of blood cells, including red and white blood cells, and platelets. This excessive production, especially of red blood cells, thickens the blood, impairing normal flow and increasing the risk of serious complications like blood clots, heart attacks, and strokes. PV can progress to conditions like myelofibrosis and leukemia. Men over 60 years are at higher risk, with an estimated incidence of two in 100,000 individuals. Besremi is indicated for PV when other therapies are inadequate.

Clinical Data: The NDA submission in Japan relied on clinical trial findings, including a Phase II trial (A19-201 study) conducted in Japan and overseas studies. FDA approval in the USA was supported by a trial involving 51 PV patients at six sites in Austria, with two additional studies providing supplementary safety data. Results indicated that 61% of Besremi-treated patients achieved desired outcomes, such as normalized blood counts, spleen size reduction, and prevention of new blood clots.

Positioning & Market Outlook: Apart from the approval for PV, Besremi is under late-stage development for other indications – it is also under a global Ph III trial for 'essential thrombocythemia' as well as studies for 'adult T-cell leukemia' and 'chronic myelocytic leukemia'.

Besremi holds a robust position in addressing polycythemia vera. According to experts in hematology and oncology, there have been no specific medications designed to halt the progression from polycythemia vera to bone marrow fibrosis and leukemia until now. The introduction of Besremi signifies a noteworthy advancement in treatment, offering the potential to prevent the transition to these diseases.

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

In PV, a number of exciting agents being developed. Some of the Ph III candidates include Rusfertide, a hepcidin mimetic from Protagonist, which is now partnered with Takeda, Bomedemstat, an LSD1 inhibitor, from Imago BioSciences (now MSD), givinostat, an HDAC inhibitor, from Italfarmaco etc. Backed by exciting new candidates, this market is expected to grow by over 10% CAGR for the next ten years.

Overseas Status: Besremi was approved by the USA-FDA for the treatment of adult patients with PV in November 2021. In the Europe, EMA approved it as a first-line monotherapy to treat PV in adult patients without symptomatic splenomegaly in February 2019. The drug is also approved in Switzerland, Taiwan, Israel and South Korea etc.

Empaveli – the first and	d only C3	3 inhibitor for	PNH
--------------------------	-----------	-----------------	-----

	Drug Profile - Empaveli					
Molecule Type	Small Molecule	Molecule	Pegcetacoplan	Brand	Empaveli	
Launch Month	September 2023	Form	Injection	Strength	1,080mg/20mL/vial	
Therapeutic Classes ^{*3} (2nd level)	Immunosuppressants	Mechanism of Action	Inhibiting not only the cleavage of C3 but also the production of downstream effectors for complement activation and Membrane-A			
Therapeutic Classes ^{*3}	Other	(MOA)	Complex (MAC) by bind			
(3rd level)	Immunosuppressants		Complex (MAC) by bind		25 protein and C5b.	
Indication	Paroxysmal Nocturnal He	oxysmal Nocturnal Hemoglobinuria (PNH)				
Manufecturer	Swedish Orphan Biovitrum Japan	Marketer	Asahi Kasei Pharma	Originator/s	Apellis Pharmaceutical	
Price Maintenance Premium (PMP)	Applied		¥488.121	Peak Sales (Predicted ^{*4})	¥11 Billion	
Total Sales of the The	rapeutic Category (Other I	mmunosuppressants) *5			¥2 Billion	
Contribution of the Brands in the Category (Other Immunosuppressants) *5					100%	
Hospital (≥100 beds)	Sales Ratio in the Categor	y (Other Immunosuppre	ssants) ^{*5}		94%	

*3...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

Empaveli is the first and only C3 inhibitor treatment for paroxysmal nocturnal hemoglobinuria (PNH). In Japan, Soliris (eculizumab) was launched in June 2010 as the first drug for PNH followed by Ultomiris (ravulizumab) in 2019. Both are C5 inhibitors and from Alexion. C5 inhibitors are currently considered as the first line treatment for PNH.

The Drug: Pegcetacoplan is made of two synthetic peptides (short chains of amino acids) linked together, which target and attach to the C3 complement protein, which is a part of the body's defense system called the 'complement system'. It not only inhibits the cleavage of C3 but also the production of downstream effectors for complement activation and Membrane-Attack Complex (MAC) by binding to complement C3 protein and C3b.

In patients with PNH, the complement proteins are over-active and damage the patients' own cells. By blocking the C3 complement protein, pegcetacoplan prevents complement proteins from damaging cells, thereby helping to relieve the symptoms of this disease.

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Empaveli is the first and only C3 inhibitor treatment for PNH that controls both types of hemolysis intravascular hemolysis (IVH, the destruction of red blood cells inside a blood vessel) and extravascular hemolysis (EVH, the destruction of red blood cells that occurs in the liver or spleen).

Pricing and Peak Sales Potential: Empaveli price was set with Soliris as the comparator drug where it was granted 5% utility premium (II). According to documents submitted to the Central Social Insurance Medical Council (Chuikyo), Empaveli is forecasted to achieve ¥11 billion in peak sales during its 10th year on the market, with an anticipated treatment of 226 patients.

Marketing and Distribution: Asahi Kasei Pharma is the local partner of Sobi in Japan, which holds the exclusive distribution rights to the drug in Japan. Globally, Swedish Orphan Biovitrum Japan (Sobi) and Apellis are partners.

About the Indication: Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare hematological condition wherein the body's immune system mistakenly attacks and destroys red blood cells, known as erythrocytes, regardless of age. Left untreated, PNH can lead to severe complications such as thrombosis, renal failure, and organ disorders.

Due to its rarity, the precise prevalence and incidence of PNH remain unknown. However, it is estimated that globally, there are approximately 15.9 individuals with PNH per 1 million people, with an annual incidence expected to be around 5 to 6 individuals per 1 million people.

Clinical Data: Empaveli was studied in two Ph III clinical trials for PNH – 1.) the PEGASUS study, which included adults with previous C5i treatment (eculizumab), and 2.) the PRINCE study, which included adults without any previous C5i treatment.

In the PEGASUS study, Empaveli demonstrated superior improvements in hemoglobin (Hb) in people who previously received eculizumab at week 16 (P<0.0001). Moreover, the Hb improvement was maintained through the 48-week study. In the PRINCE study, 86% of people taking Empaveli achieved Hb stabilization and 46% of people taking Empaveli achieved Hb normalization over 26 weeks.

Positioning & Market Outlook: Soliris from Alexion was launched on June 2010 as the first drug for PNH in Japan. Later it was approved for other indications also. Until then, hematopoietic stem cell transplantation was used to perform for certain patients. Ultomiris, another drug from Alexion, was the next drug for the PNH which joined the NHI price listing in September 2019. Ultomiris offered extended dosing interval of once every eight weeks (one-fourth the injection frequency of Soliris). Both the Soliris and Ultomiris are C5 inhibitors. C5 inhibitors are currently considered as the first line treatment for PNH.

Empaveli was priced with Soliris as the comparator drug and earned a 5% utility premium. In Japan, Empaveli's recommended dose schedule for adults is subcutaneous injection (1 vial of 1080 mg) twice a week, which can be increased to once every three days if not effective.

Empaveli conducted trails in patients previously treated with C5 inhibitors (eculizumab) as well as in patients who were previously untreated with C5 inhibitors. However, its results from the former study appears more convincing. In Europe, Empaveli is recommended to be used in patients who continue to have anaemia despite treatment with C5 inhibitors for at least 3 months.

A number of new drugs are also approaching the market. These include Crovalimab from Chugai, which is an anti-C5 recycling antibody, Pozelimab from Regeneron, also an anti-C5 antibody etc. In January, 2024, Voydeya (danicopan) from Alexionpharma was approved as the first-in-class, oral, Factor D inhibitor as an ad-on therapy for PNH patients on C5 inhibitors. Globally, over two dozen drugs are under clinical development for PNH and growth can be expected in this market.

Overseas Status: Pegcetacoplan is approved for the treatment of PNH in the United States (it was approved initially in May 2021 and later self-administrating injector was approved in October 2023; in the USA it is sold under the brand name Empaveli), European Union (approved in December 2021; sold under the brand name Aspaveli), and other countries globally. The therapy is also under investigation for some other rare diseases across hematology and nephrology. In February of 2023, the UDA FDA also approved pegcetacoplan (under the brand name Syfovre) as the first in class treatment for GA (Geographic atrophy; a late stage of non-neovascular age-related macular degeneration (non-nAMD)).

		Drug Pro	file - Epkinly		
Molecule Type	Biologics(mAb)	Molecule	Epcoritamab (genetical recombination)	Brand	Epkinly
Launch Month	November 2023	Form	Injection	Strength	4mg/0.8mL/vial 48mg/0.8mL/vial
Therapeutic Classes ^{*3} (2nd level)	Antineoplastics	Mechanism of Action	T-cell dependent cellular	atotovicity	`
Therapeutic Classes ^{*3}	Monoclonal Antibody	(MOA)	r-cell dependent cellular	cytotoxicity	
(3rd level)	Antineoplastics				
Indication	 - The following recurrent or refractory large B-cell lymphoma - Diffuse large B cell lymphoma - High grade B cell lymphoma - Primary mediastinal large B-cell lymphoma - Recurrent or refractory follicular lymphoma 				
Manufecturer	Genmab	Marketer	Genmab	Originator/s	Genmab
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥137,724, ¥1,595,363	Peak Sales (Predicted ^{*4})	¥30.7 Billion
otal Sales of the Therapeutic Category (Monoclonal Antibody Antineoplastics) ^{*5} ¥1,060 Billion					¥1,060 Billion
Contribution of the Br	ands in the Category (Mon	oclonal Antibody Antine	eoplastics) ^{*5}		90%
Hospital (≥100 beds)	Sales Ratio in the Category	(Monoclonal Antibody	Antineoplastics) *5		98%

Epkinly - the first anti-CD20xCD3 bispecific antibody for LBCL

*3...Encise's Anatomical Therapeutic Chemical Classification

*4...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

Epkinly was NHI listed and launched on the same day in November 2023 as the first T-cell engaging bispecific antibody for the treatment of certain types of relapsed or refractory (r/r) large B-cell lymphoma (LBCL).

The Drug: Epkinly is a IgG1 bispecific antibody directed towards certain types of relapsed or refractory LBCL. The drug is designed to slow disease progression by simultaneously binding to CD3 on T cells and CD20 on B cells and inducing the T cell-mediated killing of CD20-positive cells. It is the first bispecific antibody directed at LBCL in Japan.

Anyone who has read the report is deemed to have agreed to the Terms of Use.

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Pricing and Peak Sales Potential: According to the data provided to Chuikyo, Epkinly is anticipated to achieve peak sales of ¥30.7 billion in its tenth year on the market, with an estimated 972 patients. It falls under the H1 category of products subject to the CEA. Epkinly was priced with Amgen's Blincyto (blinatumomab) as the comparator and was granted a 10% utility premium (II).

Marketing and Distribution: The drug was jointly developed by Genmab and AbbVie as part of their oncology collaboration. Genmab is a marketing authorization holder (MAH) in Japan, while promotions will be run together with AbbVie.

About the Indication: Epkinly is indicated for the treatment of certain types of relapsed or refractory LBCL (diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma), and relapsed or refractory follicular lymphoma (FL), after two or more lines of systemic therapy. LBCL is a non-Hodgkin's lymphoma (NHL) that progresses rapidly with abnormalities occurring in B-cell lymphocytes (a type of white blood cell).

DLBCL is the most common type of NHL worldwide, accounting for approximately 30 percent of all NHL cases and comprising an estimated 30,400 U.S. cases in 2022. DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men.

As per national cancer center survey report in 2019, the total number of newly diagnosed cases of malignant lymphoma in Japan were 36,638 and this figure has grown at 4.6% 10 years compound annual growth rate (CAGR).

Clinical Data: Epkinly was evaluated in a single-arm clinical trial called EPCORE NHL-1, consisting of three segments: Phase 1 (first-in-human, dose-escalation), Phase 2a (expansion), and Phase 2a (optimization). The accelerated approval by the FDA was based on data from the expansion cohort of 157 patients with r/r LBCL.

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Of the 157 patients enrolled, 148 had DLBCL or high-grade B-cell lymphoma, with 86% diagnosed with DLBCL not otherwise specified (NOS). The study aimed to assess Epkinly's safety and effectiveness at the recommended Phase 1 dose across three patient cohorts with various r/r B-cell NHL types and limited treatment options.

Epkinly demonstrated an overall response rate of 61%, including a 39% complete response rate. The median response duration was 15.6 months.

Positioning & Market Outlook: The competition in the anti-CD20 bispecific space is taking shape as a number of big players are expected to enter the market soon.

In March 2024, Chugai has filed an NDA for its anti-CD20xCD3 bispecific antibody mosunetuzumab for the treatment of patients with r/r follicular lymphoma (FL) who have received two or more prior systemic therapies. It was already approved by the USA FDA in Dec 2022 under the brand name Lunsumio. Another anti-CD20xCD3 bispecific antibody from Chugai glofitamab is currently under development in Japan. It is also already approved by the USA FDA (in June, 2023) under the brand name Columvi for the treatment of adult patients with r/r DLBCL NOS or LBCL arising from FL, after two or more lines of systemic therapy. Other candidates from the same category under-development include candidates from Regeneron and Johnson & Johnson (in partnership with Xencor).

Overseas Status: Epcoritamab received accelerated approval from the USA FDA in May 2023 (under brand name Epkinly), and it received conditional approval from the European commission in September 2023 (under brand name Tepkinly).

		Drug Pro	file - Leqembi		
Molecule Type	Biologics(mAb)	Molecule	Lecanemab (genetical recombination)	Brand	Leqembi
Launch Month	December 2023	Form	Injection	Strength	200mg/2mL/vial 500mg/5mL/vial
Therapeutic Classes ^{*3} (2nd level)	Other CNS Drugs	Mechanism of Action	Binding to and neutraliz	ation of soluble amy	loid-beta (Αβ) oligomers and
Therapeutic Classes ^{*3} (3rd level)	Anti-Alzheimer Products	(MOA)	promotion of A β clearance from the brain.		
Indication	Inhibition of progression of	of mild cognitive impair	ment (MCI) and mild der	mentia due to Alzheir	ner's disease
Manufecturer	Eisai	Marketer	Eisai	Originator/s	BioArctic Neuroscience
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥45,777, ¥114,443	Peak Sales (Predicted ^{*4})	¥98.6 Billion
Total Sales of the Therapeutic Category (Anti-Alzheimer Products) ^{*5}					¥35 Billion
Contribution of the Brands in the Category (Anti-Alzheimer Products) ^{*5}					2%
Hospital (≥100 beds)	Sales Ratio in the Category	(Anti-Alzheimer Produc	cts) *5		28%

Leqembi - the first disease-modifying therapy for AD

^{*3}...Encise's Anatomical Therapeutic Chemical Classification

*4...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

Leqembi was approved in September 2023, for people with mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD). It is the first AD-modifying therapy approved in Japan and had the highest forecasted peak-sales among all drugs approved in 2023.

The Drug: Lecanemab is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody (mAb) designed to target both aggregated soluble and insoluble forms of the A β peptide, which constitutes the primary component of the amyloid plaques present in the brains of individuals with AD. The buildup of amyloid beta plaques in the brain stands as a crucial pathophysiological characteristic of AD. Lecanemab selectively binds to neutralize and remove soluble toxic A β aggregates that may potentially affect disease pathology and slow the disease progression. Leqembi can only be used in people diagnosed with AD with the presence of A β pathology suggested through amyloid PET scans or cerebrospinal fluid testing.

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Pricing and Peak Sales Potential: The NHI pricing of Leqembi was established through a cost-based method, involving a "usefulness premium (I)" of 45%. This premium was fully applied due to the product's extensive manufacturing cost transparency (premium coefficient: 1.0). Additionally, Leqembi met the requirements for the post-launch price maintenance premium (PMP).

According to these criteria, it is priced at ¥45,777 per 200mg/2 mL vial and ¥114,443 per 500mg/5 mL vial. Consequently, the anticipated annual cost of Leqembi per patient is approximately ¥2.98 million, which falls below the estimated US\$26,500 per year per patient (or roughly ¥3.88 million) in the USA. Data submitted to the Chuikyo suggests that Leqembi is projected to achieve a peak sale of ¥98.6 Billion by treating 32,000 patients in the ninth year following its launch.

About the Indication: AD is a subtype of dementia, which gradually progresses and affects both cognition and behavior. Exact physiology is not known but the role of 'amyloid cascade hypothesis' is widely accepted, which causes the shrinkage of brain tissues and loss of neurons. As per the Ministry of Health, Labour and Welfare (MHLW), estimated about 6 million of elderly over 65 of age have dementia as of 2020, and this is expected to rise to about 7 million by 2025. Growing elderly population makes Japan one of the highest AD prevalent countries among the developed nations.

Clinical Data: The approval of Leqembi was backed on the data from the landmark Phase III Clarity AD clinical study. This study had enrolled 1,795 people with early AD aged from 50 to 90 years and randomised them to receive either a dosage of 10mg/kg of lecanemab every two weeks or a placebo. The primary endpoint of the study was the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months. The mean change of CDR-SB from baseline at 18 months was 1.21 and 1.66 for lecanemab and placebo groups, respectively.

The individuals treated with Lecanemab showed a statistically significant reduction by -0.45 in clinical decline on the global cognitive and functional scale, compared with placebo at 18 months, representing a 27% slowing of clinical decline.

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Positioning & Market Outlook: After the genericization of major products in 2020, the AD market sales continue to fall sharply. In 2023, the total AD market was ¥36.7 billion (-24% YoY and -29% 3-year compound annual growth rate (CAGR)). There has been no new drug since 2011 in AD in Japan (until Leqembi). However, in the near future, tremendous growth is expected due to the rapidly aging population and the entry of high-priced, disease-modifying drugs like Leqembi.

In Japan, the number of patients with MCI and mild dementia due to AD, which is Leqembi's targeted indication, is estimated at 5.42 million. However, the therapy's actual utilization will be restricted under "optimal use promotion guidelines" that will precisely outline eligibility criteria for patients, facilities, and physicians.

Donanemab, an anti-Aβ antibody from Eli Lilly, is a close competitor candidate of Leqembi. The Ph III study 'TRAILBLAZER-ALZ 2' demonstrated that donanemab significantly slowed cognitive and functional decline in people with early symptomatic AD. Donanemab was filed in Japan in September, 2023.

Overseas Status: Lecanemab received breakthrough therapy designation from the US FDA for the treatment of AD in June 2021 and subsequently was grated accelerated approval in January 2023. Later, supplemental biologics license application (sBLA) was filed supported by the findings from Clarity AD Phase III data for securing the complete approval. In Europe, Eisai submitted a marketing authorization application (MAA) for the drug to the European Medicines Agency (EMA) in January 2023, which was subsequently accepted in the same month. The EMA recommended refusing the marketing authorization for the drug in July 2024.

	Drug Profile - Leqvio					
Molecule Type	Nucleic Acid	Molecule	Inclisiran sodium	Brand	Leqvio	
Launch Month	November 2023	Form	Injection	Strength	300mg/1.5mL/syringe	
Therapeutic Classes ^{*3}	Lipid-regulating/Anti-			•		
(2nd level)	atheroma Preparations	Machanism of Action	Inhibition of Dronzotoin co	nuartasa subtilisin (kavi		
Therapeutic Classes ^{*3}	Cholesterol and	(MOA)		/kexin type 9 (PCSK9)		
(3rd level)	Triglyceride Regulating		production by RNA interference			
(Sta level)	Preparations					
	Familial hypercholesterolemia, hypercholesterolemia					
Indication	However, only if both of the following apply.					
Indication	- High risk of cardiovascular events					
	- Inadequate response to HMG-CoA reductase inhibitors or unsuitable for treatment with HMG-CoA reductase inhibitors					
Manufecturer	Novartis Pharma	Marketer	Novartis Pharma	Originator/s	Alnylam Pharmaceuticals	
Price Maintenance	Applied	Unit Price (at the time	¥443.548	Peak Sales	¥19.5 Billion	
Premium (PMP)	Applied	of first listing)	±443,340	(Predicted ^{*4})	+19.5 DIIION	
Total Sales of the Ther	¥135 Billion					
Contribution of the Br	Contribution of the Brands in the Category (Cholesterol and Triglyceride Regulating Preparations) *5 26%					
Hospital (≥100 beds)	Sales Ratio in the Category	(Cholesterol and Trigly	ceride Regulating Preparation	ons) ^{*5}	22%	

Leqvio - the first siRNA therapy for hypercholesterolemia

^{*3}...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

Novartis launched Leqvio in November 2023 soon after its listing. Leqvio is the first siRNA therapy for dyslipidemia approved in Japan. All other siRNA therapies approved so far in Japan are for rare diseases.

The Drug: Inclisiran exerts its effect by preventing the formation of PCSK9 protein, allowing more LDL receptors to remove circulating LDL-C. After administration, it is slowly released into the cytoplasm and loads onto the RNA-induced silencing complex (RISC). Once loaded, it works with RISC to sequentially cleave multiple copies of PCSK9 protein mRNA, which continuously prevents PCSK9 production. Less PCSK9 allows for increased LDL-C receptors to bind to and decrease circulating LDL-C.

Pricing and Peak Sales Potential: Leqvio was priced by comparator method (I) referring to Amgen's Repatha (evolocumab). For its novel mechanism of action it was granted a utility premium (I) of 40%. Its peak sales is estimated to be ¥19.5B in the 10th year on the market, with 29,000 patients expected, as per the data submitted to MHLW. It will be also subject to the CEA under the H1 product category.

Marketing and Distribution: Novartis will market the drug in Japan. Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals.

About the Indication: Leqvio is approved for both familial and non-familial hypercholesterolemia. It will be prescribed for patients meeting two criteria: 1) at high risk of cardiovascular events and 2) showing inadequate responses to or unsuitability for HMG-CoA reductase inhibitors. Guidelines promoting optimal usage will be developed to outline specific eligibility criteria for facilities and patients. Optimal use promotion guidelines are to be compiled to specify more detailed eligibility criteria for facilities and patients.

Clinical Data: Leqvio's approval was supported by results from a placebo-controlled, double-blind, randomized Phase III clinical trial programs, including ORION-9, ORION-10, and ORION-11 trials. ORION-9 was a global trial conducted at 46 sites across eight countries, enrolling 482 patients with Heterozygous Familial Hypercholesterolemia (HeFH). In ORION-10, held at 145 US sites, and ORION-11, conducted at 70 sites across seven countries, patients with Atherosclerotic cardiovascular disease (ASCVD) were studied. Additionally, the approval was also backed upon Japanese Phase II trial ORION-15.

In ORION-9, Leqvio reduced LDL-C by 48% compared to placebo at 17 months. ORION-10, with 1,561 ASCVD participants, demonstrated a 52% reduction in LDL-C compared to placebo at 17 months and a 54% reduction from three to 18 months. ORION-11, with 1,617 ASCVD or risk equivalent patients, showed a 50% reduction in LDL-C compared to placebo.

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Positioning & Market Outlook: Leqvio carries the exact same indication as Amgen's PCSK9 inhibitor Repatha. However, there is little difference in terms of their expected effects. While Repatha requires subcutaneous injections every two to four weeks, Leqvio offers a significantly extended dosing interval, with injections only every six months during the maintenance phase. This longer interval is particularly advantageous for patient adherence, especially for older individuals who may find self-injections challenging. Specialists recognize the potential of Leqvio to improve patient compliance, particularly among those with poor adherence profiles, thereby reducing treatment dropouts. The less frequent dosing regimen of Leqvio, requiring injections only twice a year, holds promise for revolutionizing the treatment of dyslipidemia.

The total dyslipidemia market was about ¥193 billion in 2023 and it continues to fall sharply (-11% YoY, and -11% 3-year compound annual growth rate (CAGR)) as the major segment statins have been heavily genericized. Going forward, however, growth can be expected in this market driven by next-generation drugs like Leqvio and high R&D activity. Entry of semaglutide in dyslipidaemia market (for diabetes patients) is also going to impact the conventional market.

Overseas Status: Leqvio is approved in more than 90 countries worldwide including the US, EU and China.

Litfulo - the second approved drug for alopecia areata

	Drug Profile - Litfulo				
Molecule Type	Small Molecule	Molecule	Ritlecitinib tosilate	Brand	Litfulo
Launch Month	September 2023	Form	Capsule	Strength	50mg/capsule
Therapeutic Classes ^{*3}	Other Dermatological				
(2nd level)	Preparations	Mechanism of Action	Inhibition of Janus kinase (JAK) 3 and TEC family kinases, tyrosine kinases		
Therapeutic Classes ^{*3}	Other Dermatological	(MOA)	expressed in hepatocellular carcinoma		
(3rd level)	Preparations				
Indication	Alopecia areata (limited t	o refractory cases where	hair loss is extensive)		
Manufecturer	Pfizer	Marketer	Pfizer	Originator/s	Pfizer
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥5,802.4	Peak Sales (Predicted ^{*4})	¥15.6 Billion
Total Sales of the Therapeutic Category (Other Dermatological Preparations) *5					¥28 Billion
Contribution of the Brands in the Category (Other Dermatological Preparations) ^{*5} 93%					93%
Hospital (≥100 beds)	Sales Ratio in the Categor	y (Other Dermatological	Preparations) *5		17%

^{*3}...Encise's Anatomical Therapeutic Chemical Classification

*4...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

Litfulo is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older, it is the second approved treatment for this indication.

The Drug: Ritlecitinib is an inhibitor of JAK3 and the TEC family kinases. Inhibition of JAK3 and TEC kinase family members by ritlecitinib may block signaling of cytokines and cytolytic activity of T cells, which is implicated in the pathogenesis of alopecia areata. Ritlecitinib is also being evaluated for vitiligo, Crohn's disease, and ulcerative colitis.

Pricing and Peak Sales Potential: Litfulo price was calculated based on the comparator method (I) by referring to Olumiant (baricitinib) and it was granted a 5% usefulness premium (II) and a 5% pediatric premium. Litfulo is eligible for the price maintenance premium (PMP) and will be subject to cost-effectiveness assessments (CEAs) under the 'H1 category' of applicable products (peak sales of over ¥10B). Peak sales are projected to reach ¥15.6 B with 11,000 patients in its 10th year on the market, as per the documents presented to the Central Social Insurance Medical Council (Chuikyo).

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Unauthorized quoting, copying and reproduction of the contents of this report are prohibited.

About the Indication: Litfulo is approved for the treatment of Alopecia Areata only in extensive and refractory cases. Alopecia Areata is an autoimmune disease characterized by patchy hair loss, which occurs when immune cells attack normal hair follicles. While hair loss commonly occurs on the scalp, it can extend to encompass the entire head and body, including facial areas like eyebrows, eyelashes, and the beard. Although the typical age of onset is between 25 and 35 years, this condition can affect individuals across various age groups, spanning from children to the elderly, irrespective of gender or race. In Japan, the prevalence of Alopecia Areata is gradually increasing, estimated to be approximately 0.2-0.3%.

Additionally, treatment options for alopecia areata are limited, and management after onset is known to be difficult. These can lead to decreased health-related quality of life in many patients, and serious psychological effects such as depression and anxiety.

Clinical Data: The approval was backed on data collected from multiple clinical trials including a global Ph II/III study, titled ALLEGRO-2b/3, as well as a PIII clinical study, ALLEGRO-LT.

The ALLEGRO-2b/3 investigated the drug in a total of 718 AA patients 12 years of age and older, with at least 50% scalp hair loss due to the disease, including alopecia totalis (complete scalp hair loss) and alopecia universalis (complete scalp, face, and body hair loss).

As per Pfizer, ritlecitinib 50 mg and 30 mg achieved the primary efficacy endpoint of the study, which was the proportion of patients with less than or equal to 20% scalp hair loss after 24 weeks of treatment versus placebo.

Positioning & Market Outlook: Various drugs have been used for years to treat Alopecia Areata, but most were not officially approved for this purpose and were used off-label or as over-the-counter (OTC) medicines. These include topical and injectable steroids, minoxidil, anthralin, cyclosporine, methotrexate, sulfasalazine, and more. The first drug officially approved for Alopecia Areata is Eli Lilly's JAK inhibitor Olumiant (baricitinib), given the additional indication by MHLW in June 2022. Olumiant, originally approved for rheumatoid arthritis and atopic dermatitis, had total sales of ¥30.6B from all indications in CY 2023. Litfulo is the second and only competitor of Olumiant for Alopecia Areata.

While the clinical studies for Olumiant (BRAVE-AA trails) and Litfulo (ALLEGRO trials) have differences in design, their findings are somewhat similar. Notably, the Litfulo study included children (age 12 and up), giving it an apparent advantage over Olumiant, which was tested only on adults (age 18-60 years). However, for effective Alopecia Areata treatment, it's crucial to sustain hair growth over an extended period. Since both drugs are relatively new and were studied for only 48 to 52 weeks in trials, we will need post-marketing studies to uncover their sustainable long-term benefits.

Overseas Status: Litfulo received approval from the US FDA in June 2023 and from the European Union in September 2023 as a treatment for severe alopecia areata in both adults and children aged 12 and above.

Mounjaro - first GIP/GLP-1	dual receptor agonist for T2DM
----------------------------	--------------------------------

Drug Profile - Mounjaro					
Molecule Type	Small Molecule	Molecule	Tirzepatide	Brand	Mounjaro
Launch Month	April 2023	Form	Injection	Strength	2.5mg/0.5mL/kit
					5mg/0.5mL/kit
					7.5mg/0.5mL/kit
					10mg/0.5mL/kit
					12.5mg/0.5mL/kit
					15mg/0.5mL/kit
Therapeutic Classes ^{*3} (2nd level)	Drugs Used in Diabetes	Mechanism of Action	Glucose-Dependent Insulinotropic Polypeptide (GIP) / Glucagon-like peptide-1 receptor agonist (GLP-1) receptors agonist		
Therapeutic Classes ^{*3}	GLP-1 Agonist	(MOA)			
(3rd level)	Antidiabetics				
Indication	Diabetes type 2		*******		
Manufecturer	Eli Lilly Japan	Marketer	Mitsubishi Tanabe Pharma	Originator/s	Eli Lilly and Company
Price Maintenance		Unit Price (at the time	¥1,924, ¥3,848, ¥5,772,	Peak Sales	
Premium (PMP)	Applied	of first listing)	¥7,696, ¥9,620, ¥11,544	(Predicted ^{*4})	¥36.7 Billion
Total Sales of the Therapeutic Category (GLP-1 Agonist Antidiabetics) *5					¥111 Billion
Contribution of the Brands in the Category (GLP-1 Agonist Antidiabetics) ^{*5}					100%
Hospital (\geq 100 beds) Sales Ratio in the Category (GLP-1 Agonist Antidiabetics) ^{*5}					27%

^{*3}...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

Mounjaro (tirzepatide) is a dual-targeted, injectable, sustained-release therapy indicated for the management of type 2 diabetes (T2D) in adults as an adjunct to diet and exercise. In Japan, it was approved in September 2022 but the listing was delayed until March 15, 2023 and it was launched on April 18, 2023. This was apparently due to its heavy demand in overseas markets.

The Drug: Mounjaro is the first and only once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist to improve blood glucose levels in adults with T2D. GIP and GLP-1 are the native incretin hormones. The activation of these receptors improves the secretion of both first and second-phase insulin and reduces glucagon levels, both in a glucose-dependent manner.

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Unauthorized quoting, copying and reproduction of the contents of this report are prohibited.

Pricing and Peak Sales Potential: In clinical trials, it has shown superior HbA1c reductions in head-tohead trials with Ozempic and Trulicity. For this, it was granted a 10% utility premium (II) over Ozempic as the comparator. Mounjaro has a projected peak sale of ¥36.7 billion in the 10th year on the market, treating 240,000 patients (as per documents presented to the Central Social Insurance Medical Council (Chuikyo)).

Marketing and Distribution: Mounjaro is originated and developed by Eli Lilly. In Japan, Eli Lilly holds its manufacturing and marketing approval, while Mitsubishi Tanabe (MTPC) is responsible for its sales and distribution. Eli Lilly Japan and MTPC will jointly provide information to healthcare professionals.

About the Indication: T2D occurs predominantly in people over the age of 40. Being overweight and sedentary life-style are one of major causes. DT2 is characterized by impaired insulin secretion and/or resistance. It is called non-insulin-dependent diabetes mellitus (NIDDM), because insulin is produced but the body's insulin receptors are relatively insensitive to the levels of insulin in the body. As per MHLW patient survey data in 2020, the total number diagnosed patients of diabetes under treatment was about 5.8 million. Estimated about 95% of them were T2D.

As per the International Diabetic Federation (IDF), Japan had a 11.8% prevalence of diabetes in adults in 2021. The prevalence of diabetes in Japan is increasing and it is mainly attributed to aging as well as growing obesity rates.

Clinical Data: Mounjaro demonstrated positive outcome in an extensive, global Phase III SURPASS programme that included five clinical trials (SURPASS-1, SURPASS-2, SURPASS-3, SURPASS-4 and SURPASS-5). In SURPASS-1, Mounjaro was studied as a monotherapy while in SURPASS-2-3 and 4, it was studied as an add-on to the metformin, sulfonylureas, and/or sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors). In SURPASS-5 it was evaluated in combination with basal insulin with or without metformin.

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Mounjaro delivered superior blood glucose level reductions against all comparators in the SURPASS programme. Patients achieved reductions of between 1.8% and 2.1% in their blood glucose levels on an average for Mounjaro 5mg, and between 1.7% and 2.4% for both 10mg and 15mg doses of Mounjaro. Additionally, Mounjaro also led to significantly greater weight loss in patients than other comparators. Patients treated with 5mg of Mounjaro lost 12lb of weight, while those given a 15mg dose saw their weight reduce by 25lb.

Positioning & Market Outlook: The total anti-diabetes drug market was ¥711.8 billion in 2023 and it continues to be one of the growing therapeutic segments in Japan (7% YoY). The dynamics of diabetes market, both for oral agents and injectable agents, is rapidly changing. The growth in the diabetes class is anticipated due to increasing diabetic population, flow of new drugs with new mechanism of actions, expanding labels, new-safety data, and combination therapies especially around SGLT-2 inhibitors and GLP-1 analogues.

GLP-1 analogues and insulins are administered through sub-cutaneous route. GLP-1 analogues posted a total sale of ¥63.8 Billion in 2023. It is a growing class (5% YoY, and 5% 3-Year CAGR) and the growth is likely to be maintained backed by the entry of high-potential new drugs like Ozempic (¥23.5 billion, 89% YoY) and Mounjaro.

Mounjaro is considered as a potential blockbuster globally. The high expectations are based on the robust clinical data it has shown. The topline data of a global Phase III trial (SURPASS-1) indicated a 2.07% reduction in HbA1c and 9.5 kg (11.0%) drop in weight, among other favourable results. It is also under development for chronic weight management, and heart failure with preserved ejection fraction (HFpEF), and for non-alcoholic steatohepatitis (NASH).

Overseas Status: The US FDA approved Mounjaro in May 2022 after granting priority review designation. It received marketing authorization from the European Union in September 2022. In October 2022, the FDA granted Fast Track designation for tirzepatide to evaluate it for the treatment of obesity, or overweight with weight-related comorbidities in adults.

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Drug Profile - Omvoh					
Molecule Type	Biologics(mAb)	Molecule	Mirikizumab (genetical recombination)	Brand	Omvoh
Launch Month	June 2023	Form	Injection	Strength	100mg/mL/kit 100mg/mL/syringe
Therapeutic Classes ^{*3} (2nd level) Therapeutic Classes ^{*3} (3rd level)	Intestinal Disorder Products Inflammatory Bowel Disorder Products	Mechanism of Action (MOA)	Inhibitory effect on Interleukin-23 (IL-23) p19		
Indication	Maintenance therapy for r	moderate to severe ulce	erative colitis (limited to cases with inadequate response to existing treatmen		
Manufecturer	Eli Lilly Japan	Marketer	Mochida Pharmaceutical	Originator/s	Eli Lilly and Company
Price Maintenance Premium (PMP)	Not applied	Unit Price (at the time of first listing)	¥126,798, ¥126,798	Peak Sales (Predicted ^{*4})	¥29.1 Billion
Total Sales of the Therapeutic Category (Inflammatory Bowel Disorder Products) *5					¥62 Billion
Contribution of the Brands in the Category (Inflammatory Bowel Disorder Products) ^{*5}					80%
Hospital (\geq 100 beds) Sales Ratio in the Category (Inflammatory Bowel Disorder Products) ^{*5}					57%

Omvoh - first IL-23 inhibitor in the crowded UC market

^{*3}...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

Omvoh was approved in Japan in March 2023 ahead of the USA or Europe. It is indicated for induction and maintenance therapy in patients with moderate to severe ulcerative-colitis (UC) who have an inadequate response to conventional treatments.

The Drug: Mirikizumab is a humanized IgG4 monoclonal antibody which targets the protein p19 subunit of human IL-23 cytokine and selectively inhibits the IL-23 pathway. Overactive IL-23 pathway is a key contributor to inflammation in UC pathogenesis. IL-23 drives mucosal inflammation by regulating T cell and innate immune cell subsets, which produce pro-inflammatory cytokines. By blocking these pathways, Mirikizumab effectively prevents the release of pro-inflammatory cytokines and chemokines.

Pricing and Peak Sales Potential: Omvoh was priced under the comparator method (I) by comparing Skyrizi (risankizumab). Omvoh comes in two formulations - an IV version for remission induction therapy and SC versions (autoinjector and syringe forms) for maintenance therapy. Together, they are expected to carry a peak-sales potential of ¥31.5 billion by treating 15,500 patients (in the 10th year), as per the data submitted at Chuikyo.

Marketing and Distribution: Through the partnership between Eli Lilly and Mochida, Lilly provides Omvoh in Japan while Mochida is responsible for its distribution, sales, and detailing activities.

About the Indication: The Inflammatory Bowel Disease (IBD) is an umbrella terms for autoimmune disorders in gastrointestinal track. Ulcerative colitis (UC) is major subtype of IBD where immune system causes inflammation and ulcers on the inner lining of colon (large intestine) and rectum. Another major subtype is Crohn's disease (CD) which mainly affects the portion of the small intestine before the colon. Ulcerative colitis can develop at any age, but the disease is more likely to develop in people between the ages of 15 and 30.

Clinical Data: In two trials known as LUCENT, Omvoh exhibited favorable outcomes as both induction and maintenance therapy for individuals with ulcerative colitis who had been previously treated. Following a 12-week induction period, 24.2% of patients receiving Omvoh attained clinical remission, compared to 13.3% in the placebo group. Throughout the maintenance phase, 63.6% of those who achieved remission with Omvoh at 12 weeks maintained it for a year, while only 36.9% of patients in the placebo group sustained remission for the same duration.

Positioning & Market Outlook: A number of biologics already available in the UC market (table 2). Although Omvoh is late from that point of view, it is the first IL-23 inhibitor to enter the crowded UC market. By selectively targeting IL-23, Omvoh is viewed as a better therapy than Stelara, which targets both IL-12 and IL-23. With multiple indications, Stelara generated ¥77.2 billion sales (14.6% YoY) in the 2023. Other biologics in the UC market include AbbVie's Humira (2023 sales ¥58.4 Billion, -6.8% YoY) and Takeda's Entyvio (2023 sales ¥17.6 Billion, 13.7% YoY).

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Meanwhile, other IL-23 inhibitors are under development for UC. These include Skyrizi (Risankizumab, which is already approved for other indications including Crohn's disease and psoriasis etc.) and Tremfya (guselkumab, which is also already approved for other indications including psoriasis, psoriatic arthritis etc.). AbbVie has already filed Skyrizi to the US FDA and the EMA based on positive phase III results.

Overseas Status: Omvoh was approved in Japan in March 2023 ahead of the USA or Europe. Omvoh was granted marketing authorization in the European Union (EU) in May 2023 for its use as induction and maintenance therapy in patients with moderate to severe UC who have an inadequate response to conventional treatments. In the USA, it was approved by the FDA in October 2023 for treating adults with moderate to severe active UC.

Brand (Molecule) Marketer	МОА	Indications including	2023 Sales
Omvoh (Mirikizumab) Mochida	Targets IL-23p19	Ulcerative Colitis	n/a
Stelara (Ustekinumab) MTPC	targets both IL-12	Crohn's Disease, Ulcerative Colitis,	¥77.2 B
	and IL-23	Psoriatic Arthritis, Psoriasis vulgaris	
Humira (adalimumab) AbbVie	TNF-α inhibitor	Rheumatoid arthritis, psoriasis	¥58.4 B
		(vulgaris, arthritis, pustular),	
		ankylosing spondylitis, juvenile	
		arthritis; Behcet's disease, ulcerative	
		colitis etc.	
Entyvio (Vedolizumab) Takeda	$\alpha_4\beta_7$ integrin blocker	ulcerative colitis and Crohn's	¥17.6 B
		disease	

Table 2: Select Biologics Approved for Ulcerative Colitis^{*6}

*6...All are genetic recombinant drugs

Source: Encise Research Center, Company Reports

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Unauthorized quoting, copying and reproduction of the contents of this report are prohibited.

Phesgo - subcutaneous FDC of Perjeta and Herceptin

Drug Profile - Phesgo					
Molecule Type	Biologics(mAb)	Molecule	Pertuzumab (genetical recombination), Trastuzumab (genetical recombination) and Vorhyaluronidase alfa (genetical recombination)	Brand	Phesgo
Launch Month	November 2023	Form	Injection	Strength	10mL/vial 15mL/vial
Therapeutic Classes ^{*3} (2nd level)	Antineoplastics	Mechanism of Action			
Therapeutic Classes ^{*3} (3rd level)	Monoclonal Antibody Antineoplastics	(MOA)	Antibody dependent cellular cytotoxicity		
Indication	- HER2-positive breast cancer - HER2-positive unresectable advanced or recurrent colorectal cancer that exacerbated after cancer chemotherapy				
Manufecturer	Chugai Pharmaceutical	Marketer	Chugai Pharmaceutical	Originator/s	Roche
Price Maintenance Premium (PMP)	Not applied	Unit Price (at the time of first listing)	¥268,695, ¥471,565	Peak Sales (Predicted ^{*4})	¥34.4 Billion
Total Sales of the Therapeutic Category (Monoclonal Antibody Antineoplastics) *5					¥1,060 Billion
Contribution of the Brands in the Category (Monoclonal Antibody Antineoplastics) *5					90%
Hospital (\geq 100 beds) Sales Ratio in the Category (Monoclonal Antibody Antineoplastics) ^{*5}				98%	

^{*3}...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

Phesgo is a fixed-dose combination of Perjeta and Herceptin - its unique formulation allows for

subcutaneous administration, reducing infusion time to five to eight minutes, potentially alleviating strain on healthcare systems and enhancing patient convenience and cost-effectiveness.

The Drug: Phesgo is a fixed-dose subcutaneous combination of two already marketed antibodies from Chugai - Perjeta (pertuzumab) and Herceptin (trastuzumab) along with vorhyaluronidase alfa. Hyaluronidase, a hyaluronic acid-degrading enzyme, is considered to enhance the dispersion and absorption of the antibodies in the combination. Phesgo is the world's first subcutaneous injection for HER2-positive colorectal cancer.

Anyone who has read the report is deemed to have agreed to the Terms of Use.

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Pricing and Peak Sales Potential: Phesgo was priced by the comparator method by referring to Perjeta and Herceptin as comparators, with no launch premium granted. As per the data submitted to the Central Social Insurance Medical Council (Chuikyo), Phesgo is expected to generate a peak sale of¥ 34.4B in the fifth year on the market, treating 9,300 patients.

About the Indication: Phesgo is indicated for Human Epidermal Growth Factor Receptor 2 (HER2)positive breast cancer as well as HER2-positive unresectable, advanced/relapsed colorectal cancer that has progressed after chemotherapy. HER2 receptors are present in all cells, whether healthy or cancerous. However, an excess of these receptors can accelerate the growth and division of cancer cells, leading to a condition known as HER2+ cancer.

Roughly 15% to 20% of breast cancer cases are estimated to be HER2-positive. According to data from the Japan National Cancer Center (NCC) in 2019, Japan saw a total of 110,728 new cases of diagnosed breast cancer, marking a 3.9% year-over-year increase and a 63.8% growth over the past decade.

For colorectal cancer, approximately 3-4% of tumors are HER2 positive. According to NCC data from 2019, the total number of newly diagnosed cases of all colon cancer during the same period was 155,625, showing a 2.2% year-over-year increase and a 33.8% growth over the past decade.

Clinical Data: The approval from the Ministry of Health, Labour and Welfare (MHLW) was based on the outcomes of the global Phase III FeDeriCa trial, conducted among patients with HER2-positive breast cancer. This trial, which was open-label, aimed to compare the pharmacokinetics, efficacy, and safety of administering Phesgo via subcutaneous injection alongside chemotherapy versus the intravenous infusion of Perjeta and Herceptin.

Encompassing 500 patients in both neoadjuvant and adjuvant settings, the primary objective was to evaluate the minimum levels of Perjeta in the bloodstream within a specific dosage timeframe, as well as to assess the overall pathological complete response in the breast and axilla following surgery, indicating the absence of detectable cancer tissue in the excised area. The study sought to determine any differences between Phesgo and Perjeta + Herceptin. The FeDeriCa trial effectively achieved its primary goal of demonstrating non-inferior levels of Perjeta in the bloodstream.

Positioning & Market Outlook: As clinical trials of Phesgo aimed to show non-inferiority to the combination of Herceptin and Perjeta, it is likely to protect the sales from the generic erosion of the two brands. Being a fixed-dose subcutaneous agent, Phesgo shortens the administration time as compared to Perjeta and Herceptin, which are both given intravenously, and requires no dose adjustment. As per Chugai, this is expected to contribute to enhance the efficiency of medical resources.

Both Herceptin and Perjeta have been mainstay products for Chugai. Herceptin sales has been declining severely as biosimilars takes the market share and it posted just ¥6.2 Billion (5 years CAGR -29%), while the sales from its biosimilars was ¥8.1 Billion in 2023. There are no biosimilars for Perjeta yet and it is still growing (2023 sales was ¥42.2 Billion, 5.6% YoY). However, as it was launched in 2013, it must be approaching the expiry of its exclusivity (re-examination period).

Overseas Status: The US FDA approved Phesgo for the treatment of eligible patients with early and metastatic HER2-positive breast cancer in June 2020. Following it USA approval, in December 2020, the European Commission granted its approval for treating HER2-positive breast cancer in adults.

Drug Profile - Phozevel								
Molecule Type	Small Molecule	Molecule	Tenapanor hydrochloride	Brand	Phozevel			
Launch Month	February 2024	Form	Tablet	Strength	5mg/tablet 10mg/tablet 20mg/tablet 20mg/tablet			
Therapeutic Classes ^{*3} (2nd level) Therapeutic Classes ^{*3} (3rd level)	All Other Therapeutic Products Hyperkalaemia/Hyperpho sphataemia Products	Mechanism of Action (MOA)	30mg/tablet					
Indication	Improvement of hyperpho	sphatemia in patients v	with chronic kidney disease	on dialysis				
Manufecturer	Kyowa Kirin	Marketer	Kyowa Kirin	Originator/s	Ardelyx			
Price Maintenance Premium (PMP)	Applied	1	¥234.1, ¥345.8, ¥510.9, ¥641.8	Peak Sales (Predicted ^{*4})	¥19.3 Billion			
Total Sales of the The	rapeutic Category (Hyperkal	aemia/Hyperphosphata	aemia Products) *5		¥57 Billion			
	ands in the Category (Hype				70%			
Hospital (≥100 beds)	Sales Ratio in the Category	(Hyperkalaemia/Hyper	ohosphataemia Products) *	5	34%			

Phozevel - a first-in-class phosphate absorption inhibitor

^{*3}...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

Kyowa Kirin launched Phozevel in February 2024 for the improvement of hyperphosphatemia in chronic kidney disease patients on dialysis.

The Drug: Phozevel is a first-in-class phosphate absorption inhibitor designed to block phosphate absorption through the paracellular pathway by inhibiting the sodium hydrogen exchanger 3 (NHE3) on intestinal epithelial cells in the gut.

Pricing and Peak Sales Potential: Phozevel price was set through comparator method (I) with Kissei's P-TOL Chewable Tablets (sucroferric oxyhydroxide) and was granted a 40% utility premium (I). Its peak sales are forecasted to be at ¥19.3B in the ninth year, with 66,000 patients targeted. It will also go through the CEA under the H1 category of products. Kyowa Kirin projects the drug to generate sales of ¥3.3 billion in its initial year of 2024.

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Marketing and Distribution: Kyowa Kirin will handle the marketing of the drug in Japan. They acquired rights for Phozevel's development and commercialization targeting cardiorenal diseases, including hyperphosphatemia, from Ardelyx in 2017. The deal involved an upfront payment of \$30M to Ardelyx, with additional milestone payments of up to \$130M for development and commercialization. Ardelyx was also entitled to receive high-teen percentage royalties on sales.

About the Indication: Phozevel is indicated for the improvement of hyperphosphatemia in chronic kidney disease patients on dialysis. Hyperphosphatemia is a serious condition, defined as resulting in elevated levels of phosphate in the blood, which affects the vast majority of the patients. The kidneys are responsible for eliminating excess phosphate and as kidney function declines, phosphate is not adequately eliminated from the body. As a result, hyperphosphatemia is a nearly universal condition among people with CKD on maintenance dialysis.

Clinical Data: Phozevel approval was based on the findings from four Phase III trials conducted in Japan on patients undergoing maintenance dialysis with hyperphosphatemia. In these studies, tenapanor, whether used alone or in combination with phosphate binders, showed a statistically significant reduction in serum phosphorus levels compared to a placebo.

Positioning & Market Outlook: Currently phosphate binders are considered as standard of care for managing hyperphosphatemia in CKD patients on dialysis. However, the majority of these patients are unable to consistently achieve target serum phosphate concentrations despite treatment with phosphate binders. Phozevel is not a phosphate binder but a phosphate absorption inhibitor. Therefore, Phozevel's complimentary mechanism of action is helpful to such patients not adequately responding to phosphate binder therapy.

Phozevel price was set by comparison method with Kissei's P-TOL. P-Tol has been in the market since 2015 and available as tablet and granule and posted ¥6.7B in CY 2023. A number of other phosphate binders available in Japan market include lanthanum carbonate (sold under brand name Fosrenol from Bayer and multiple GE companies, total sales in CY 2023 ¥12.4B), Calcium carbonate (sold from multiple companies, CY 2023 sales ¥1.2B), Sevelamer (sold under brand names Phosblock from Kyowa-Kirin) and Renagel (from Chugai, total sales ¥0.9B in CY 2023) etc.

As per MHLW patients survey report, the total number of patients with CKD in Japan was approximately 629,000 (64% males and 36% females) in 2020. Another study mentioned that approximately 350,000 people in Japan are on chronic dialysis, and this number continues to increase.

Considering the unique position Phozevel offers and the large size of the target market, Phozevel sales is likely to pick up early. Kyowa Kirin has estimated that it would generate sales of ¥3.3 B in its initial year of 2024.

Overseas Status: In October 2023, tenapanor was approved by the USA FDA under the Brand name Xphoza to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. Earlier in September 2019, tenapanor was also approved by the US FDA for the treatment of irritable bowel syndrome with constipation (IBS-C) under the brand name Ibsrela.

		Drug Prof	file - Rystiggo			
Molecule Type	Biologics(mAb)	Molecule	Rozanolixizumab (genetical recombination)	Brand	Rystiggo	
Launch Month	November 2023	Form	Injection	Strength	280mg/2mL/vial	
Therapeutic Classes ^{*3} (2nd level)	Immunosuppressants	Mechanism of Action	Inhibition of Immunoglob	ng and transcytosis by blocking		
Therapeutic Classes ^{*3}	Other	(MOA)	IgG binding to Neonatal Fc receptor (FcRn)			
(3rd level)	Immunosuppressants					
Indication	Generalized myasthenia	gravis (limited to cases w	ith inadequate response to	steroids or non-st	eroidal immunosuppressants)	
Manufecturer	UCB Japan	Marketer	UCB Japan	Originator/s	UCB	
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥356,392	Peak Sales (Predicted ^{*4})	¥20.4 Billion	
Total Sales of the The	rapeutic Category (Other I	mmunosuppressants) *5			¥112 Billion	
Contribution of the Br	ands in the Category (Oth	er Immunosuppressants) *5		77%	
Hospital (≥100 beds)	Sales Ratio in the Categor	y (Other Immunosuppre	ssants) *5		58%	

Rystiggo - gMG treatment for the two main sub-types

*3...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

Rystiggo was launched in November 2023 for the treatment of generalized myasthenia gravis (gMG).

The Drug: Rystiggo is a humanized IgG4 monoclonal antibody that targets the human neonatal Fc receptor (FcRn), inhibiting its interaction with Immunoglobulin G (IgG). This process enhances the catabolism of antibodies and lowers the levels of pathogenic IgG autoantibodies. By facilitating intracellular IgG degradation, Rystiggo effectively reduces circulating IgG concentrations.

Pricing and Peak Sales Potential: Rystiggo's pricing was determined using the comparator method (I) and it received a 10% marketability premium due to its orphan designation. According to the data presented to Chuikyo, its peak sales are estimated to reach ¥20.4 billion, based on treating 1,300 patients in the tenth year on the market.

About the Indication: Rystiggo is indicated for treating adult patients with gMG, but only in those who inadequately respond to steroids or other immunosuppressants.

Myasthenia gravis (MG) is a chronic autoimmune disorder in which antibodies destroy the communication between nerves and muscle, resulting in weakness of the skeletal muscles. MG affects the voluntary muscles of the body, especially those that control the eyes, mouth, throat and limbs. MG has two main types: ocular Myasthenia Gravis (oMG), affecting eye and eyelid muscles, and generalized MG (gMG), causing weakness in multiple muscle groups. It is more common in young women (20-30 years old) and men aged 50 and above. The global prevalence is estimated to be around 150 to 350 cases per 1,000,000 people. There are three main sub-types of MG:

- 1. Anti-acetylcholine receptor (AChR) subtype anti-AChR antibodies are detected in 85% to 95% of patients with gMG, and 40% to 70% in oMG.
- Muscle-specific tyrosine kinase (MuSK) subtype anti-MuSK antibodies are detected in 7% to 10% of all patients with MG and up to 40% of patients who test negative for anti-AChR antibodies.
- 3. Lipoprotein receptor-related protein 4 (LRP4) accounts for 2% to 50% of double seronegative MG cases.

Clinical Data: The approval was supported by findings from the crucial Phase III MycarinG clinical trial. The main effectiveness measure of the trial was assessing the difference in Myasthenia Gravis-Activities Daily Living Profile (MG-ADL) total scores between treatment groups at day 43 compared to baseline. The MG-ADL evaluates the impact of generalized Myasthenia Gravis (gMG) on eight routine activities, including breathing, speaking, swallowing, and mobility. The reductions in MG-ADL score from baseline to day 43 were more significant in the Rystiggo groups compared to the placebo group.

Rystiggo has demonstrated efficacy both in anti-AChR antibody-positive gMG and anti-MuSK antibodypositive gMG, the two most common subtypes of the disease.

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Positioning & Market Outlook: The drugs traditionally used for the management of gMG include 1. Cholinesterase inhibitors (e.g. pyridostigmine etc.) to improve communication between nerves and muscles. 2. Corticosteroids (e,g, prednisone etc.) to block the immune system making it less able to produce antibodies. 3. Immunosuppressants (e,g, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate etc.). However, none of them cure the disease but slows the progression or provide symptomatic relief but all of them have side effect profile. In some patients removing thymus gland is found to be effective.

Next generation drugs include the complement inhibitors and neonatal Fc receptor (FcRn) blockers. Soliris (recombinant eculizumab) was the first complement inhibitor for gMG. Ultomiris (ravulizumab) and Zilbrysq (zilucoplan) are also C5-inhibitors. While, Vyvgart (efgartigimod alfa) and Rystiggo (Rozanolixizumab) both are neonatal FcRn blockers.

UCB received approval for two gMG drugs in September 2023, Rystiggo and Zilbrysq. While Rystiggo was launched in November soon after both products were NHI listed, Zilbrysq was launched in February 2024. Zilbrysq is indicated for gMG only in cases with inadequate responses to steroids or other immunosuppressants. It is the first self-injectable subcutaneous treatment for gMG in Japan. As per the data submitted to the Central Social Insurance Medical Council (Chuikyo), its peak sales are projected at ¥8.9B in the 10th year on the market.

Given the substantial unmet need in the field of MG and the recent introduction of promising candidates, significant market growth can be expected in this area. Among late stage pipline candidates, Mitsubishi Tanabe is developing Uplizna (inebilizumab), which an anti-CD-19 mAb, licensed from Amgen (Horizon earlier).

Overseas Status: The USA FDA approved the drug in June 2023 for the treatment of gMG, following the orphan drug designation granted in 2019. Rystiggo received a marketing authorisation valid throughout the EU in January 2024. It was also granted orphan drug designation by the European Commission in April 2020.

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.

Profile of New Molecular Entities Listed in 2023, excluding the drugs which are described above

Tavalisse

	Drug Profile - Tavalisse								
Molecule Type	Small Molecule	Molecule	Fostamatinib sodium hydrate Brand Tavalisse						
Launch Month	April 2023	Form	Tablet	Strength	100mg/tablet 150mg/tablet				
Therapeutic Classes ^{*3} (2nd level) Therapeutic Classes ^{*3} (3rd level)	Blood Coagulation System, Products Platelet-Enhancing Products	Mechanism of Action (MOA)	Spleen tyrosine kinase (SYK) inhibitor						
Indication	Chronic idiopathic throm	bocytopenic purpura							
Manufecturer	Kissei Pharmaceutical	Marketer	Kissei Pharmaceutical	Originator/s	Rigel Pharmaceuticals				
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)			¥6.0 Billion				
Total Sales of the The	apeutic Category (Platelet	-Enhancing Products) *5	******		¥45 Billion				
Contribution of the Brands in the Category (Platelet-Enhancing Products) *5					100%				
Hospital (≥100 beds)	Sales Ratio in the Categor	y (Platelet-Enhancing Pro	ducts) *5		76%				

Cresemba (Oral)

Drug Profile - Cresemba								
Molecule Type	Small Molecule	Molecule	Isavuconazonium sulfate	Brand	Cresemba			
Launch Month	April 2023	Form	Capsule	Strength	100mg/capsule			
Therapeutic Classes ^{*3}	Systemic Agents for							
(2nd level)	Fungal Infections	Mechanism of Action	Inhibition of call membrar					
Therapeutic Classes ^{*3}	Systemic Agents for	(MOA)	Progressive Pulmonary Aspergillosis (CPPA), Simple Pulmon					
(3rd level)	Fungal Infections							
	Treatment of the following	g mycoses:						
	OAspergillosis (invasive a	spergillosis, Chronic Pro	gressive Pulmonary Asper	gillosis (CPPA), Simple	Pulmonary Aspergillosis			
Indication	(SPA))							
	OMucormycosis							
	OCryptococcosis (pulmo	nary cryptococcosis, dis	Isavuconazonium sulfate Brand Capsule Strength Inhibition of cell membrane synthesis ogressive Pulmonary Aspergillosis (CPI seminated cryptococcosis (including c Asahi Kasei Pharma Originato ¥4,505.7 Peak Sale ctions) *5	including cryptococcal	meningitis))			
Manufecturer	Asahi Kasei Pharma	Marketer	Asahi Kasei Pharma	Originator/s	Basilea Pharmaceutica			
Price Maintenance	Netenalised	Unit Price (at the time		Peak Sales	¥3.4 Billion			
Premium (PMP)	Not applied	of first listing)	±4,303.7	(Predicted ^{*4})	+5.4 DIIION			
Total Sales of the The	rapeutic Category (Systemi	c Agents for Fungal Infe	ections) *5		¥35 Billion			
	rands in the Category (Syste				64%			
Hospital (≥100 beds)	Sales Ratio in the Category	(Systemic Agents for F	ungal Infections) *5		63%			

*3...Encise's Anatomical Therapeutic Chemical Classification

*4...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Paxlovid

	Drug Profile - Paxlovid								
Molecule Type	Small Molecule	Molecule	Nirmatrelvir and Ritonavir	Brand	Paxlovid				
Launch Month	February 2022	Form	Tablet	Ctropath	300mg(nirmatrelvir)/sheet				
Launch Month	February 2022	FOIIII	Tablet	Strength	600mg(nirmatrelvir)/sheet				
Therapeutic Classes ^{*3}	Antivirals for Systemic Use								
(2nd level)	Antivitais for Systemic Ose	Mechanism of Action	Inhibitory effect on 3CL pr	otosco					
Therapeutic Classes*3	Antivirals Other	(MOA)	minibitory effect on SCL pr						
(3rd level)	Antivirals, Other								
Indication	SARS-CoV-2 infection								
Manufecturer	Pfizer	Marketer	Pfizer	Originator/s	Pfizer				
Price Maintenance	Applied	Unit Price (at the time	¥12,538.6, ¥19,805.5	Peak Sales	¥28.1 Billion				
Premium (PMP)	Applied	of first listing)	+12,556.0, +19,605.5	(Predicted ^{*4})	+20.1 DIIII011				
Total Sales of the The	rapeutic Category (Antivirals	, Other) *5			¥81 Billion				
Contribution of the Brands in the Category (Antivirals, Other) *5					77%				
Hospital (≥100 beds)	Sales Ratio in the Category	(Antivirals, Other) ^{*5}			23%				

Monover

Drug Profile - Monover								
Molecule Type	Others	Molecule	Ferric derisomaltose	Brand	Monover			
Launch Month	March 2023	Form	Injection	Strength	500mg/5mL/vial 1,000mg/10mL/vial			
Therapeutic Classes ^{*3} (2nd level)	Anti-anaemic Preparations	Mechanism of Action	Iron cumplementation					
Therapeutic Classes ^{*3}	Haematinics, Iron and All	(MOA)	Iron supplementation					
(3rd level)	Combinations							
Indication	Iron Deficiency Anemia (ID	A)						
Manufecturer	Nippon Shinyaku	Marketer	Nippon Shinyaku	Originator/s	Pharmacosmos			
Price Maintenance	Not applied	Unit Price (at the time	¥6.189. ¥12.377	Peak Sales	¥2.0 Billion			
Premium (PMP)	Not applied	of first listing)	+0,109, +12,377	(Predicted ^{*4})	+2.0 Billon			
Total Sales of the The	rapeutic Category (Haematir	nics, Iron and All Comb	inations) ^{*5}		¥7 Billion			
Contribution of the Br	Contribution of the Brands in the Category (Haematinics, Iron and All Combinations) ^{*5}							
Hospital (≥100 beds)	Sales Ratio in the Category	(Haematinics, Iron and	All Combinations) *5		38%			

^{*3}...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Erwinase

	Drug Profile - Erwinase								
Molecule Type	Biologics(not mAb)	Molecule	Crisantaspase	Brand	Erwinase				
Launch Month	June 2023	Form	Injection	Strength	10,000U/vial				
Therapeutic Classes ^{*3} (2nd level)	Antineoplastics	Mechanism of Action	Hudrolucis of Lasparaci						
Therapeutic Classes ^{*3} (3rd level)	All Other Antineoplastics	(MOA)	Hydrolysis of L-asparagine						
Indication	Acute leukemia (including Limited to those who show		. 5 , 1						
Manufecturer	Ohara Pharmaceutical	Marketer	Ohara Pharmaceutical	Originator/s	Health Protection Agency				
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥172,931	Peak Sales (Predicted ^{*4})	¥0.73 Billion				
Total Sales of the The	rapeutic Category (All Other	Antineoplastics) *5	·····		¥44 Billion				
Contribution of the Br	Contribution of the Brands in the Category (All Other Antineoplastics) *5								
Hospital (≥100 beds)	Sales Ratio in the Category	(All Other Antineoplast	ics) ^{*5}		84%				

Imjudo

Drug Profile - Imjudo								
Molecule Type	Biologics(mAb)	Molecule	Tremelimumab (genetical recombination)	Brand	Imjudo			
Launch Month	March 2023	Form	Injection	Strength	25mg/1.25mL/vial 300mg/15mL/vial			
Therapeutic Classes ^{*3} (2nd level)	Antineoplastics	Mechanism of Action	Cutatovie T. humphonita a	(CTLA A) inhibitor				
Therapeutic Classes ^{*3} (3rd level)	Monoclonal Antibody Antineoplastics	(MOA)	Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitor					
Indication	①Unresectable hepatocel ②Unresectable progressiv		ell lung cancer					
Manufecturer	AstraZeneca	Marketer	AstraZeneca	Originator/s	Pfizer			
Price Maintenance Premium (PMP)	Not applied	Unit Price (at the time of first listing)	¥214,801, ¥2,311,819	Peak Sales (Predicted ^{*4})	¥7.5 Billion			
Total Sales of the The	apeutic Category (Monocle	onal Antibody Antineop	lastics) ^{*5}		¥1,060 Billion			
Contribution of the Br	ands in the Category (Mon	oclonal Antibody Antin	eoplastics) *5		90%			
Hospital (≥100 beds)	Sales Ratio in the Category	(Monoclonal Antibody	Antineoplastics) *5		98%			

*3...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Libtayo

	Drug Profile - Libtayo								
Molecule Type	Biologics(mAb)	Molecule	Cemiplimab (genetical recombination)	Brand	Libtayo				
Launch Month	March 2023	Form	Injection	Strength	350mg/7mL/vial				
Therapeutic Classes ^{*3} (2nd level)	Antineoplastics	Mechanism of Action	Inhibition of PD-1/PD-L1						
Therapeutic Classes ^{*3} (3rd level)	Monoclonal Antibody Antineoplastics	(MOA)							
Indication	Progressive or recurrent of	cervical cancer that exace	rbated after cancer chemo	otherapy					
Manufecturer	Sanofi	Marketer	Sanofi	Originator/s	Regeneron Pharmaceuticals				
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥450,437	Peak Sales (Predicted ^{*4})	¥2.3 Billion				
Total Sales of the The	apeutic Category (Monocl	onal Antibody Antineop	lastics) *5		¥1,060 Billion				
Contribution of the Br	Contribution of the Brands in the Category (Monoclonal Antibody Antineoplastics) *5								
Hospital (≥100 beds)	Sales Ratio in the Categor	y (Monoclonal Antibody	Antineoplastics) *5		98%				

Adtralza

	Drug Profile - Adtralza								
Molecule Type	Biologics(mAb)	Molecule	Tralokinumab (genetical recombination)	Brand	Adtralza				
Launch Month	September 2023	Form	Injection	Strength	150mg/mL/syringe				
Therapeutic Classes ^{*3} (2nd level)	Nonsteroidal Products for Inflammatory Skin Disorders	Mechanism of Action							
Therapeutic Classes ^{*3} (3rd level)	Other Nonsteroidal Products for Inflammatory Skin Disorders	(MOA)	Inhibition of interleukin-1						
Indication	Atopic dermatitis with inad	lequate response to exi	sting treatments						
Manufecturer	Leo Pharma	Marketer	Leo Pharma	Originator/s	Cambridge Antibody Technology				
Price Maintenance Premium (PMP)	Not applied	Unit Price (at the time of first listing)	¥29,295	Peak Sales (Predicted ^{*4})	¥4.4 Billion				
Total Sales of the The	rapeutic Category (Other No	nsteroidal Products for	r Inflammatory Skin Disord	ers) *5	¥28 Billion				
Contribution of the Br	rands in the Category (Other	Nonsteroidal Products	for Inflammatory Skin Dis	orders) *5	93%				
Hospital (≥100 beds)	Sales Ratio in the Category	(Other Nonsteroidal Pr	oducts for Inflammatory SI	kin Disorders) *5	17%				

*3...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Cresemba (Injection)

Drug Profile - Cresemba								
Molecule Type	Small Molecule	Molecule	Isavuconazonium sulfate	Brand	Cresemba			
Launch Month	April 2023	Form	Injection	Strength	200mg/vial			
Therapeutic Classes ^{*3}	Systemic Agents for							
(2nd level)	Fungal Infections	Mechanism of Action	labibition of call accordance					
Therapeutic Classes ^{*3}	Systemic Agents for	(MOA)	Inhibition of cell membrar					
(3rd level)	Fungal Infections							
Indication	Treatment of the following mycoses: OAspergillosis (invasive aspergillosis, Chronic Progressive Pulmonary Aspergillosis (CPPA), Simple Pulmonary Aspergillosis (SPA)) OMucormycosis OCryptococcosis (pulmonary cryptococcosis, disseminated cryptococcosis (including cryptococcal meningitis))							
Manufecturer	Asahi Kasei Pharma	Marketer	Asahi Kasei Pharma	Originator/s	Basilea Pharmaceutica			
Price Maintenance Premium (PMP)	Not applied	Unit Price (at the time of first listing)	¥27,924	Peak Sales (Predicted ^{*4})	¥0.56 Billion			
Total Sales of the The	rapeutic Category (Systemi	c Agents for Fungal Infe	ctions) *5		¥35 Billion			
Contribution of the Br	ands in the Category (Syste	emic Agents for Fungal	Infections) *5		64%			
Hospital (≥100 beds)	Sales Ratio in the Category	(Systemic Agents for F	ungal Infections) *5		63%			

Allydone

Drug Profile - Allydone								
Molecule Type	Small Molecule	Molecule	Donepezil	Brand	Allydone			
Launch Month	April 2023	Form	Adhesive Skin Patch	Strength	27.5mg/sheet 55mg/sheet			
Therapeutic Classes ^{*3} (2nd level)	Other CNS Drugs	Mechanism of Action	Powersible inhibition of a	ACHE				
Therapeutic Classes ^{*3} (3rd level)	Anti-Alzheimer Products	(MOA)	Reversible inhibition of acetylcholinesterase (AChE)					
Indication	Inhibition of progression of	of cognitive symptoms	in Alzheimer's Disease (A	D)				
Manufecturer	Teikoku Seiyaku	Marketer	Kowa	Originator/s	Eisai			
Price Maintenance Premium (PMP)	Not applied	Unit Price (at the time of first listing)	¥289.8, ¥441.4	¥2.6 Billion				
Total Sales of the The	rapeutic Category (Anti-Alzł	neimer Products) *5	x		¥35 Billion			
Contribution of the B	Contribution of the Brands in the Category (Anti-Alzheimer Products) *5							
Hospital (≥100 beds)	Sales Ratio in the Category	(Anti-Alzheimer Produc	ts) *5		28%			

*3...Encise's Anatomical Therapeutic Chemical Classification

*4...according to the Ministry of Health, Labour and Welfare (MHLW)
 *5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Xocova

Drug Profile - Xocova								
Molecule Type	Small Molecule	Molecule	Ensitrelvir fumaric acid	Brand	Хосоvа			
Launch Month	November 2022	Form	Tablet	Strength	125mg/tablet			
Therapeutic Classes ^{*3} (2nd level)	Antivirals for Systemic Use	Mechanism of Action	labibitany offect on 201					
Therapeutic Classes ^{*3} (3rd level)	Antivirals, Other	(MOA)	Inhibitory effect on 3CL					
Indication	SARS-CoV-2 infection		K					
Manufecturer	Shionogi	Marketer	Shionogi	Originator/s	Hokkaido University, Shionogi			
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥7,407.4	Peak Sales (Predicted ^{*4})	¥19.2 Billion			
Total Sales of the The	rapeutic Category (Antivirals,	, Other) *5			¥81 Billion			
Contribution of the Br	ands in the Category (Antivi	rals, Other) ^{*5}			77%			
Hospital (≥100 beds)	Sales Ratio in the Category	(Antivirals, Other) *5			23%			

Doptelet

	Drug Profile - Doptelet								
Molecule Type	Small Molecule	Molecule	Avatrombopag maleate	Brand	Doptelet				
Launch Month	June 2023	Form	Tablet	Strength	20mg/tablet				
Therapeutic Classes ^{*3}	Blood Coagulation								
(2nd level)	System, Products	Mechanism of Action	Thrombonoiotin (TPO) roc	optor stimulating activi	ts /				
Therapeutic Classes ^{*3}	Platelet-Enhancing	(MOA)	MOA) Thrombopoietin (TPO) receptor stimulating activity						
(3rd level)	Products								
Indication	Improvement of thrombo	cytopenia in patients w	th chronic liver disease sch	eduled for elective inva	sive procedures				
Manufecturer	Swedish Orphan	Marketer	Asahi Kasei Pharma	Originator/s	Astellas Pharma				
Manufecturer	Biovitrum Japan	IVIAI KELEI		Oliginatorys					
Price Maintenance	Not applied	Unit Price (at the time	¥7,106.6	Peak Sales	¥0.07 Billion				
Premium (PMP)		of first listing)	+1,100.0	(Predicted ^{*4})					
Total Sales of the Ther	apeutic Category (Platelet-E	Enhancing Products) *5			¥45 Billion				
Contribution of the Br	Contribution of the Brands in the Category (Platelet-Enhancing Products) ^{*5}								
Hospital (≥100 beds)	Sales Ratio in the Category	(Platelet-Enhancing Pro	ducts) *5		76%				

*3...Encise's Anatomical Therapeutic Chemical Classification

*4...according to the Ministry of Health, Labour and Welfare (MHLW)

^{*5}...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Orphacol

Drug Profile - Orphacol								
Molecule Type	Small Molecule	Molecule	Cholic acid Brand Orphacol					
Launch Month	June 2023	Form	Capsule	Strength	50mg/capsule			
Therapeutic Classes ^{*3} (2nd level)	Sbiliary Tract and Liver Disorder Products	Mechanism of Action	Suppression of abnormal bile acids synthesis Mechanism of Action improvement of cholestasis associated with ir					
Therapeutic Classes ^{*3} (3rd level)	Biliary Tract Disorder Products	(MOA)	secretion of bile acids into bile, and absorption enhancement of fats and fat-soluble vitamins					
Indication	Inborn Errors of Bile Acid	Metabolism (IEBAM)	•••••••••••••••••••••••••••••••••••••••					
Manufecturer	Reqmed	Marketer	Reqmed	Originator/s	Laboratoires CTRS			
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥12,596	Peak Sales (Predicted ^{*4})	¥0.23 Billion			
Total Sales of the The	rapeutic Category (Biliary Tr	act Disorder Products)	5		¥10 Billion			
Contribution of the Br	ands in the Category (Biliar	y Tract Disorder Produc	ts) ^{*5}		1%			
Hospital (≥100 beds)	Sales Ratio in the Category	(Biliary Tract Disorder P	roducts) ^{*5}		30%			

Vyalev

		Drug Pro	ofile - Vyalev			
Molecule Type	Small Molecule	Molecule	Foslevodopa and Foscarbidopa hydrate	Brand	Vyalev	
Launch Month	July 2023	Form	Injection	Strength	10mL/vial	
Therapeutic Classes ^{*3} (2nd level)	Anti-parkinson Drugs	Mechanism of Action	Effect of increased dona	rt on dona decarbovylase		
Therapeutic Classes ^{*3} (3rd level)	Anti-Parkinson Drugs	(MOA)	Effect of increased dopamine, inhibitory effect on dopa decarboxylase			
Indication	Improvement of diurnal with existing medical treat		, , ,		hich is not sufficiently effective	
Manufecturer	Abbive	Marketer	Abbive	Originator/s	AbbVie	
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥13,277	Peak Sales (Predicted ^{*4})	¥9.6 Billion	
Total Sales of the The	rapeutic Category (Anti-Pa	rkinson Drugs) ^{*5}			¥95 Billion	
Contribution of the Br	rands in the Category (Ant	i-Parkinson Drugs) *5			63%	
Hospital (≥100 beds)	Sales Ratio in the Categor	y (Anti-Parkinson Drugs)	*5		43%	

*3...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

^{*5}...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Omvoh (Maintenance therapy)

		Drug Pro	file - Omvoh			
Molecule Type	Biologics(mAb)	Molecule	Mirikizumab (genetical recombination)	Brand	Omvoh	
Launch Month	June 2023	Form	Injection	Strength	300mg/15mL/vial	
Therapeutic Classes ^{*3} (2nd level)	Intestinal Disorder Products	Mechanism of Action	Inhibitory effect on Interle	}		
Therapeutic Classes ^{*3} (3rd level)	Inflammatory Bowel Disorder Products	(MOA)				
Indication	Remission induction the treatment)	rapy for moderate to seve	ere ulcerative colitis (limite	d to cases with ina	dequate response to existing	
Manufecturer	Eli Lilly Japan	Marketer	Mochida Pharmaceutical	Originator/s	Eli Lilly and Company	
Price Maintenance Premium (PMP)	Not applied	Unit Price (at the time of first listing)	¥192,332	Peak Sales (Predicted ^{*4})	¥2.4 Billion	
Total Sales of the The	apeutic Category (Inflam	matory Bowel Disorder Pr	oducts) *5		¥62 Billion	
Contribution of the Br	ands in the Category (Inf	lammatory Bowel Disorde	er Products) *5		80%	
Hospital (≥100 beds)	Sales Ratio in the Catego	ry (Inflammatory Bowel D	isorder Products) *5		57%	

Palynziq

	Drug Profile - Palynziq								
Molecule Type	Biologics(not mAb)	Molecule	Pegvaliase (genetical recombination)	Brand	Palynziq				
Launch Month	May 2023	Form	Injection	Strength	2.5mg/0.5mL/syringe 10mg/0.5mL/syringe 20mg/mL/syringe				
Therapeutic Classes ^{*3} (2nd level) Therapeutic Classes ^{*3} (3rd level)	Other Alimentary Tract and Metabolism Products Other Alimentary Tract and Metabolism Products	Mechanism of Action (MOA)	of Action Enzyme replacement therapy for Phenylalanine Ammonia Lyase (PAL) enzyme						
Indication	Phenylketonuria								
Manufecturer	Biomarin Pharmaceutical Japan	Marketer	Biomarin Pharmaceutical Japan	Originator/s	IBEX Technologies				
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥61,606, ¥64,155, ¥65,468	Peak Sales (Predicted ^{*4})	¥3.6 Billion				
Total Sales of the The	rapeutic Category (Other Ali	mentary Tract and Met	abolism Products) *5		¥110 Billion				
Contribution of the Br	ands in the Category (Other	Alimentary Tract and N	Metabolism Products) *5		59%				
Hospital (≥100 beds)	Sales Ratio in the Category	(Other Alimentary Tract	and Metabolism Products	·) ^{*5}	67%				

*3...Encise's Anatomical Therapeutic Chemical Classification

 $^{\ast 4} \mbox{...according to the Ministry of Health, Labour and Welfare (MHLW)}$

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Atgam

		Drug Pro	ofile - Atgam			
Molecule Type	Small Molecule	ecule Molecule Anti-human thymocyte immunoglobulin, equine Brand				
Launch Month	July 2023	Form	Injection	Strength	250mg/5mL/tube	
Therapeutic Classes ^{*3} (2nd level)	Sera and Gamma-globulin	Mechanism of Action				
Therapeutic Classes ^{*3} (3rd level)	Other Specific Immunoglobulins	(MOA)	MOA)			
Indication	Moderate to severe Aplast	ic Anemia (AA)				
Manufecturer	Pfizer	Marketer	Pfizer	Originator/s	Pfizer	
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥75,467	Peak Sales (Predicted ^{*4})	¥0.81 Billion	
Total Sales of the The	rapeutic Category (Other Sp	ecific Immunoglobulins	5) ^{*5}		¥1 Billion	
Contribution of the Br	ands in the Category (Other	Specific Immunoglob	ulins) ^{*5}		100%	
Hospital (≥100 beds)	Sales Ratio in the Category	(Other Specific Immune	oglobulins) ^{*5}		67%	

Nexobrid

	Drug Profile - Nexobrid								
Molecule Type	Small Molecule	Molecule	Anacaulase-bcdb (Purified pineapple stem juice)	Brand	Nexobrid				
Launch Month	August 2023	Form	Gelling Agent	Strength	5g/bottle (with mixing gel)				
Therapeutic Classes ^{*3} (2nd level) Therapeutic Classes ^{*3} (3rd level)	Other Dermatological Preparations Other Dermatological Preparations	Mechanism of Action (MOA)							
Indication	Removal of necrotic tissue	e in deep dermal burn o	r deep burns						
Manufecturer	Kaken Pharmaceutical	Marketer	Kaken Pharmaceutical	Originator/s	MediWound				
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥162,995.9	Peak Sales (Predicted ^{*4})	¥0.88 Billion				
Total Sales of the Ther	apeutic Category (Other De	ermatological Preparatio	ons) ^{*5}		¥10 Billion				
Contribution of the Br	Contribution of the Brands in the Category (Other Dermatological Preparations) *5								
Hospital (≥100 beds)	Sales Ratio in the Category	(Other Dermatological	Preparations) *5		11%				

*3...Encise's Anatomical Therapeutic Chemical Classification

*4...according to the Ministry of Health, Labour and Welfare (MHLW)
 *5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Sunlenca (Oral)

	Drug Profile - Sunlenca								
Molecule Type	Small Molecule	Molecule	Lenacapavir sodium	Brand	Sunlenca				
Launch Month	September 2023	Form	Tablet	Strength	300mg/tablet				
Therapeutic Classes ^{*3} (2nd level)	Antivirals for Systemic Use	Mechanism of Action	Capsid inhibition						
Therapeutic Classes ^{*3} (3rd level)	HIV Antivirals	(MOA)							
Indication	Multidrug resistant HIV-1 i	nfection							
Manufecturer	Gilead Sciences	Marketer	Gilead Sciences	Originator/s	Gilead Sciences				
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥94,814.2	Peak Sales (Predicted ^{*4})	¥0.0033 Billion				
Total Sales of the Ther	apeutic Category (HIV Antiv	irals) ^{*5}			¥72 Billion				
Contribution of the Br		99%							
Hospital (≥100 beds)	Sales Ratio in the Category	(HIV Antivirals) ^{*5}			85%				

Sunlenca (Injection)

	Drug Profile - Sunlenca								
Molecule Type	Small Molecule	Molecule	Lenacapavir sodium	Brand	Sunlenca				
Launch Month	September 2023	Form	Injection	Strength	1.5mL/2vials/set				
Therapeutic Classes ^{*3} (2nd level)	Antivirals for Systemic Use	Mechanism of Action	Capsid inhibition						
Therapeutic Classes ^{*3} (3rd level)	HIV Antivirals	(MOA)							
Indication	Multidrug resistant HIV-1 i	nfection							
Manufecturer	Gilead Sciences	Marketer	Gilead Sciences	Originator/s	Gilead Sciences				
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥3,208,604	Peak Sales (Predicted ^{*4})	¥0.45 Billion				
Total Sales of the The	rapeutic Category (HIV Antiv	virals) ^{*5}			¥72 Billion				
Contribution of the Br	Contribution of the Brands in the Category (HIV Antivirals) ^{*5}								
Hospital (≥100 beds)	lospital (≥100 beds) Sales Ratio in the Category (HIV Antivirals) ^{*5}								

*3...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Lytgobi

Drug Profile - Lytgobi									
Molecule Type	Small Molecule	Molecule	Futibatinib	Brand	Lytgobi				
Launch Month	September 2023	Form	Tablet	Strength	4mg/tablet				
Therapeutic Classes ^{*3} (2nd level)	Antineoplastics	Mechanism of Action	Fibroblast growth factor	4°					
Therapeutic Classes ^{*3}	Protein Kinase Inhibitor	(MOA)	TIDIODIAST GIOWITTACION	bition					
(3rd level)	Antineoplastics								
Indication	FGFR2 fusion-positive unr	resectable biliary tract ca	ncer that exacerbated aft	er cancer chemothera	ару				
Manufecturer	Taiho Pharmaceutical	Marketer	Taiho Pharmaceutical	Originator/s	Taiho Pharmaceutical				
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥10,252.5	Peak Sales (Predicted ^{*4})	¥0.37 Billion				
Total Sales of the The	rapeutic Category (Protein I	Kinase Inhibitor Antineo	plastics) *5		¥505 Billion				
Contribution of the Br	90%								
Hospital (≥100 beds)	lospital (≥100 beds) Sales Ratio in the Category (Protein Kinase Inhibitor Antineoplastics) ^{*5}								

Oncaspar

Drug Profile - Oncaspar								
Molecule Type	Biologics(not mAb)	Molecule	Pegaspargase	Brand	Oncaspar			
Launch Month	October 2023	Form	Injection	Strength	3,750IU/vial			
Therapeutic Classes ^{*3} (2nd level)	Antineoplastics	Mechanism of Action	Asparasina daamidatia					
Therapeutic Classes ^{*3} (3rd level)	All Other Antineoplastics	(MOA)	Asparagine deamidation effect					
Indication	Acute Lymphocytic Leuker	nia (ALL), Malignant Lyn	nphoma (ML)					
Manufecturer	Nihon Servier	Marketer	Nihon Servier	Originator/s	Enzon Pharmaceuticals			
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥230,637	Peak Sales (Predicted ^{*4})	¥0.52 Billion			
Total Sales of the The	rapeutic Category (All Other	Antineoplastics) *5			¥44 Billion			
Contribution of the Br	100%							
Hospital (≥100 beds)	Hospital (≥100 beds) Sales Ratio in the Category (All Other Antineoplastics) ^{*5}							

*3...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Acthib

		Drug Pro	ofile - Acthib		
Molecule Type	Others (Vaccine)	Molecule	Haemophilus b conjugate vaccine (tetanus toxoid conjugate)	Brand	Acthib
Launch Month	December 2008	Form	Injection	Strength	10µg/vial (with solution)
Therapeutic Classes ^{*3} (2nd level)	Vaccines	Mechanism of Action	Mechanism of Action Activation of B cells and production of specific antibodies (IgG) to the Haemophilus influenzae type B		
Therapeutic Classes ^{*3} (3rd level)	Bacterial Vaccines	(MOA)			
Indication	Prevention of Haemop	hilus influenzae type b infe	ction		
Manufecturer	Sanofi	Marketer	Sanofi	Originator/s	Sanofi
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)			
Total Sales of the The	rapeutic Category (Bacte	rial Vaccines) *5	•) ••••••••••••••••••••••••••••••••••••		¥18 Billion
Contribution of the Br	ands in the Category (Ba	acterial Vaccines) *5			100%
Hospital (≥100 beds)	Sales Ratio in the Categ	ory (Bacterial Vaccines) *5			11%

Luxturna

		Drug Prof	ile - Luxturna			
Molecule Type	Regenerative Medical Product	Molecule	Voretigene neparvovec	Brand	Luxturna	
Launch Month	August 2023	Form	Injection	Strength	0.5mL/vial (with 2 diluents)	
Therapeutic Classes ^{*3} (2nd level)	Ophthalmologicals	Mechanism of Action				
Therapeutic Classes ^{*3} (3rd level)	Other Ophthalmologicals	(MOA)	RPE65 gene supplementation therapy			
Indication	Hereditary retinal dystroph	ny due to RPE65 bialleli	c mutations			
Manufecturer	Novartis Pharma	Marketer	Novartis Pharma	Originator/s	The Childrens Hospital of Philadelphia	
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥0.5 Billion			
Total Sales of the The	rapeutic Category (Other Op	ohthalmologicals) *5			¥2 Billion	
Contribution of the B	rands in the Category (Other	r Ophthalmologicals) *5			96%	
Hospital (≥100 beds)	Sales Ratio in the Category	(Other Ophthalmologie	cals) ^{*5}		17%	

*3...Encise's Anatomical Therapeutic Chemical Classification

 $^{\ast 4} \mbox{...according to the Ministry of Health, Labour and Welfare (MHLW)}$

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Korsuva

		Drug Pro	file - Korsuva		
Molecule Type	Small Molecule	Molecule	Difelikefalin acetate	Brand	Korsuva
Launch Month	December 2023	Form	Injection	Strength	17.5μg/0.7mL/syringe 25μg/0.7mL/syringe 35μg/0.7mL/syringe
Therapeutic Classes ^{*3} (2nd level)	Anti-pruritics, Including Topical Antihistamines, Anaesthetics, etc Anti-pruritics, Including	Mechanism of Action (MOA)	Selective kappa-opioid re	eceptor agonist	
Therapeutic Classes ^{*3} (3rd level)	Topical Antihistamines, Anaesthetics, etc				
Indication	Improvement of pruritus i	n hemodialysis patients	(limited to cases with ina	dequate response to e	existing treatment)
Manufecturer	Maruishi Pharmaceutical	Marketer	Kissei Pharmaceutical	Originator/s	Ferring Pharmaceuticals
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥2,971, ¥3,609, ¥4,341	¥4.4 Billion	
Total Sales of the The	rapeutic Category (Anti-pru	ritics, Including Topical	Antihistamines, Anaesthet	ics, etc) *5	¥9 Billion
Contribution of the Br	ands in the Category (Anti-	pruritics, Including Topi	cal Antihistamines, Anaest	thetics, etc) *5	18%
Hospital (≥100 beds)	Sales Ratio in the Category	(Anti-pruritics, Including	g Topical Antihistamines, A	Anaesthetics, etc) *5	34%

Megludase

		Drug Profi	le - Megludase		
Molecule Type	Biologics(not mAb)	Molecule	Glucarpidase (genetical recombination)	Brand	Megludase
Launch Month	January 2024	Form	Injection	Strength	1,000/bottle
Therapeutic Classes ^{*3}	All Other Therapeutic		3	•	
(2nd level)	Products	Mechanism of Action	Mathatrovata dogradation		
Therapeutic Classes ^{*3}	Detoxifying Agents for	(MOA)	Methotrexate degradation		
(3rd level)	Antineoplastic Treatment				
Indication	Detoxification during delay	ed methotrexate excre	tion using methotrexate-leu	covorin rescue therap	у
Manufecturer	Ohara Pharmaceutical	Marketer	Ohara Pharmaceutical	Originator/s	Health Protection Agency Porton Down
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥2,674,400	Peak Sales (Predicted ^{*4})	¥0.84 Billion
Total Sales of the The	rapeutic Category (Detoxifyi	ng Agents for Antineor	plastic Treatment) *5		¥6 Billion
Contribution of the Br	ands in the Category (Deto:	xifying Agents for Antir	neoplastic Treatment) *5		33%
Hospital (≥100 beds)	Sales Ratio in the Category	(Detoxifying Agents fo	r Antineoplastic Treatment)	*5	91%

*3...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Zilbrysq

		Drug Pro	file - Zilbrysq			
Molecule Type	Small Molecule	Molecule	Zilucoplan sodium	Brand	Zilbrysq	
Launch Month	February 2024	Form	Injection	Strength	16.6mg/0.416mL/syringe 23mg/0.574mL/syringe 32.4mg/0.81mL/syringe	
Therapeutic Classes ^{*3} (2nd level)	Other Drugs for Disorders of the Musculo-skeletal System	Mechanism of Action (MOA)	5 5	5	and C6 by binding to human	
Therapeutic Classes ^{*3} (3rd level)	All Other Musculoskeletal Products		complement protein (hc5)			
Indication	Generalized myasthenia gr	avis (limited to cases w	ith inadequate response	e to steroids or non-st	eroidal immunosuppressants)	
Manufecturer	UCB Japan	Marketer	UCB Japan	Originator/s	Ra Pharmaceuticals	
Price Maintenance Premium (PMP)	Not applied	Unit Price (at the time of first listing)	¥8.9 Billion			
Total Sales of the The	rapeutic Category (All Other	Musculoskeletal Produ	cts) ^{*5}		¥112 Billion	
Contribution of the Br	ands in the Category (All Ot	her Musculoskeletal Pro	oducts) ^{*5}		77%	
Hospital (≥100 beds)	Sales Ratio in the Category	(All Other Musculoskele	etal Products) *5		58%	

Alhemo

		Drug Pro	file - Alhemo			
Molecule Type	Biologics(mAb)	Molecule	Concizumab (genetical recombination)	Brand	Alhemo	
Launch Month	February 2024	Form	Injection	Strength	15mg/1.5mL/kit 60mg/1.5mL/kit 150mg/1.5mL/kit	
(2nd level)	Blood Coagulation System Products Blood Coagulation Products	Mechanism of Action (MOA)	Hemostasis/Suppressing the inhibitory effect of activated blood coagul factor X by tissue factor pathway inhibitor (TFPI)			
Indication	Supression of bleeding te or IX	endency in patients with	congenital hemophilia wh	o have inhibitors to	blood coagulation factor VIII	
Manufecturer	Novo Nordisk Pharma	Marketer	Novo Nordisk Pharma	Originator/s	Novo Nordisk	
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥249,546, ¥844,727, ¥1,893,013	Peak Sales (Predicted ^{*4})	¥2.0 Billion	
Total Sales of the The	apeutic Category (Blood C	Coagulation Products) *5			¥151 Billion	
Contribution of the Br	ands in the Category (Bloc	d Coagulation Products) *5		100%	
Hospital (≥100 beds)	Sales Ratio in the Categor	y (Blood Coagulation Pro	oducts) ^{*5}		78%	

^{*3}...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Cuvitru

		Drug Pro	file - Cuvitru		
Molecule Type	Others	Molecule	pH4 treated human normal immunoglobulin	Brand	Cuvitru
Launch Month	January 2024	Form	Injection	Strength	2g/10mL/vial 4g/20mL/vial 8g/40mL/vial
Therapeutic Classes ^{*3} (2nd level)	Sera and Gamma-globulin	Mechanism of Action	Anticon noutralization (nb.		ing action (immunomodulation
Therapeutic Classes ^{*3} (3rd level)	Polyvalent Immuno- globulins - Intramuscular	(MOA)	Antigen neutralization/phagocytosis-enhancing action/immunomodulation		
Indication	Aggammaglobulinemia or	hypogammaglobuline	mia		
Manufecturer	Takeda Pharmaceutical	Marketer	Takeda Pharmaceutical	Originator/s	Baxter International
Price Maintenance Premium (PMP)	Not applied	Unit Price (at the time of first listing)	¥21,882, ¥43,195, ¥85,266	Peak Sales (Predicted ^{*4})	¥2.9 Billion
Total Sales of the The	rapeutic Category (Polyvaler	nt Immuno-globulins -	Intramuscular) ^{*5}		¥10 Billion
	ands in the Category (Polyv				100%
Hospital (≥100 beds)	Sales Ratio in the Category	(Polyvalent Immuno-g	obulins - Intramuscular) *5		61%

Fetroja

		Drug Pro	ofile - Fetroja				
Molecule Type	Small Molecule	Molecule	Cefiderocol tosilate sulfate hydrate	Brand	Fetroja		
Launch Month	December 2023	Form	Injection	Strength	1g/vial		
Therapeutic Classes [*] (2nd level)	³ Systemic Antibacterials	Mechanism of Action					
Therapeutic Classes [*] (3rd level)	³ Cephalosporins	(MOA)	Inhibition of bacterial cell wall synthesis				
Indication		ella pneumoniae, Klebsie a, Burkholderia, Stenotro			, Morganella morganii, e susceptible to Cefiderocol.		
Manufecturer	Shionogi	Marketer	Shionogi	Originator/s			
	jeineneg.		Shienegi	onginatorys	Shionogi		
Price Maintenance Premium (PMP)	Applied	Unit Price (at the time of first listing)	¥20.203	Peak Sales (Predicted ^{*4})	Shionogi ¥1.5 Billion		
Premium (PMP)		Unit Price (at the time of first listing)	¥20.203	Peak Sales			
Premium (PMP) Total Sales of the Th	Applied	Unit Price (at the time of first listing) osporins) ^{*5}	¥20.203	Peak Sales	¥1.5 Billion		

^{*3}...Encise's Anatomical Therapeutic Chemical Classification

^{*4}...according to the Ministry of Health, Labour and Welfare (MHLW)

*5...therapeutic category sales based on ATC 3 level in year 03/2024

Source: Encise Research Center, MHLW disclosures

We insist that you must read the terms of use at the end of this report (the "Terms of Use").

Anyone who has read the report is deemed to have agreed to the Terms of Use.

Research Report | Copyright © 2024 Encise Inc. All Rights Reserved.

Appendix: New Molecular Entities Approvals in Past 10 Years - Key Statistics (Figures only)




Figure 7. New Molecular Entities vs Peak Sales

Source: MHLW, Encise Research Center




Figure 8. New Molecular Entities Listing by Formulation Type

Source: MHLW, Encise Research Center

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.




Figure 9. New Molecular Entities Listing by Pricing Method

Source: MHLW, Encise Research Center




Figure 10. New Molecular Entities Listing by PMP vs Non-PMP

Source: MHLW, Encise Research Center

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.




Figure 11. New Molecular Entities Listing by Sponsor's Origin of Country

Source: MHLW, Encise Research Center




Figure 12. New Molecular Entities Listing by Type of Modality

Source: MHLW, Encise Research Center

We insist that you must read the terms of use at the end of this report (the "Terms of Use"). Anyone who has read the report is deemed to have agreed to the Terms of Use.



Terms of Use

Therapeutic Classes are based on Encise's original classification.

Encise Research Center has prepared this Report by processing, editing, and developing estimates based on the ethical drug information Encise has collected. Encise does not guarantee the accuracy, completeness, comprehensiveness, fitness for purpose, and currentness of the information in this Report, or that it meets any specific threshold in terms of content and/or quality.

Encise and Encise Research Center assume no responsibility for any damage or disadvantage whatsoever caused by the use of this information.

Unless otherwise indicated, all of the content of the Report is owned by Encise, and Encise reserves all the rights including, but not limited to, copyrights contained or expressed in or relating to the Report, and they are protected by applicable laws. No one, except with and to the extent of the prior written consent of Encise, shall transfer the Report to any person or let any person use the Report, or quote, reproduce or copy any and all part of the Report.

Encise Research Center

MFPR Shibuya bldg., 2-5, Shibuya 1-chome, Shibuya-ku, Tokyo 150-0002, Japan Phone: +81-3-6712-6339 Fax: +81-3-6712-6343